var title_f1_15_1264="Lupus panniculitis";
var content_f1_15_1264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus panniculitis (lupus profundus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous nodules (chest and abdomen) and lipoatrophy (upper arm) in lupus panniculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Scott Crater, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1264=[""].join("\n");
var outline_f1_15_1264=null;
var title_f1_15_1265="LCDD in small intestine";
var content_f1_15_1265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light chain deposition disease in the small intestine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunoperoxidase stain of a small intestinal biopsy from a patient with light chain deposition disease and malabsorption shows the presence kappa light chains; a stain for lambda light chains was negative.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1265=[""].join("\n");
var outline_f1_15_1265=null;
var title_f1_15_1266="Cortical hyperemia associated with focal seizures";
var content_f1_15_1266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cortical hyperemia associated with increased flow-related enhancement in a patient in focal status epilepticus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) MR angiogram showing dilatation of the right middle cerebral artery (MCA) branches presumably reflecting increased blood flow to the active cortex. B) Intra-operative photograph showing right motor strip exposed beneath the dura (right and panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Doherty, CP, Cole, AJ, Grant, PE, et al. Multimodal longitudinal imaging of focal status epilepticus. Can J Neurol Sci 2004; 31:276. Copyright &copy; Canadian Journal of Neurological Sciences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1266=[""].join("\n");
var outline_f1_15_1266=null;
var title_f1_15_1267="Pentafluoropropane and tetrafluoroethane: Drug information";
var content_f1_15_1267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentafluoropropane and tetrafluoroethane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/45/43731?source=see_link\">",
"    see \"Pentafluoropropane and tetrafluoroethane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F595554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gebauer's Instant Ice&trade; [OTC];",
"     </li>",
"     <li>",
"      Gebauer's Pain Ease&reg;;",
"     </li>",
"     <li>",
"      Gebauer's Spray and Stretch&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F595558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anesthetic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F595575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Myofascial pain, restricted motion, muscle tension:",
"     </b>",
"     Topical: Spray skin over affected muscle (include muscle attachment over trigger point, through and over the reference zone) from a distance of 12-18 inches (30-46 cm) at a rate of ~4 inches/second (10 cm/second); passively stretch muscle during spray application; may repeat if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Temporary relief of minor sports injury, preinjection anesthesia, anesthetic in minor surgery and muscle spasms:",
"     </b>",
"     Topical: Dosage varies with duration of application; use smallest dose necessary. Spray over affected area for 4-10 seconds from a distance of 3-7 inches (8-18 cm); spray until skin begins to turn white; do not frost the skin. Reapply as needed. When using for muscle spasm, gently stretch muscle immediately after application.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F595578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gebauer's Spray and Stretch&reg;: Pentafluoropropane 95% and tetrafluoroethane 5% (103.5 mL) [available in fine stream spray]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gebauer's Pain Ease&reg;: Pentafluoropropane 95% and tetrafluoroethane 5% (103.5 mL) [available in mist spray or medium stream spray]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gebauer's Instant Ice&trade; [OTC]: Pentafluoropropane 95% and tetrafluoroethane 5% (103.5 mL) [available in mist spray or stream spray]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F595556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F595576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Discontinue if skin becomes irritated. Avoid use in eyes. Do not use near face, open wounds, abraded skin, puncture wounds, animal bites, or genital mucous membranes. When used for local tissue freezing, adjacent skin areas should be protected with petroleum. Avoid use on unaffected areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Myofascial pain: Aim the spray so it meets the skin at an acute angle. Direct in parallel sweeps 0.5-1 inches (1.5-2 cm) apart at the rate of 4 inches/second (10 cm/second). Passively stretch the muscle during application; increase the force of the stretch with successive sweeps. As the muscle relaxes, establish a new stretch length. For complete pain relief, the full, normal length of the muscle must be reached. Apply moist heat for 10-15 minutes after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sports injuries (minor), preinjection anesthesia, topical anesthesia in minor surgery: Spray continuously for 4-10 seconds until the skin begins to turn white (do not frost skin/area). Anesthetic action lasts a few seconds to 1 minute.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F595559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Management of myofascial pain, restricted motion, and muscle tension; temporary relief of muscle spasm and minor sports injuries (eg, bruises, contusions, cuts/abrasions, swelling, minor sprains, strains); control of pain associated with injections or minor surgical procedures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F595565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Dermatologic: Skin irritation, skin pigmentation change, frostbite",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F595560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to pentafluoropropane, tetrafluoroethane, or any other component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F595561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation: Discontinue if skin becomes irritated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin pigmentation: Overuse may alter skin pigmentation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Do not use in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Poor circulation: Do not use in patients with poor circulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid use in eyes; do not use on large areas of damaged skin, puncture wounds, animal bites, serious wounds, or genital mucous membranes. Do not use in patients with insensitive skin. Provides temporary relief (&lt;1 minute) in sports injuries; initiate other therapy as soon as possible. If used to produce local freezing, protect adjacent skin areas with petroleum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: Do not spray near face, on open wounds, or abraded skin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2200214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F595572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Vapocoolant (skin refrigerant) and counterirritant",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14456122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration of action: Anesthetic effect: Seconds to 1 minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kostopoulos D and Rizopoulos K, &ldquo;Effect of Topical Aerosol Skin Refrigerant (Spray and Stretch Technique) on Passive and Active Stretching,&rdquo;",
"      <i>",
"       J Bodyw Mov Ther",
"      </i>",
"      , 2008, 12(2):96-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1267/abstract-text/19083662/pubmed\" id=\"19083662\" target=\"_blank\">",
"        19083662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9454 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1267=[""].join("\n");
var outline_f1_15_1267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595554\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595558\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595575\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062253\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595578\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595556\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595576\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595559\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595565\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595560\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595561\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299844\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222206\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2200214\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F595572\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456122\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/45/43731?source=related_link\">",
"      Pentafluoropropane and tetrafluoroethane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_15_1268="Heart attack symptoms PI";
var content_f1_15_1268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Heart attack symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 664px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the main symptoms of a heart attack. People who are having a heart attack often have only some of these symptoms. The pain, pressure, and discomfort caused by a heart attack mostly affect the left side of the body (shown in darker red) but can also affect the right. If you think you are having a heart attack, call 9-1-1 for an ambulance. Do not try to get yourself to the hospital.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1268=[""].join("\n");
var outline_f1_15_1268=null;
var title_f1_15_1269="Diphenhydramine (topical): Drug information";
var content_f1_15_1269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=see_link\">",
"    see \"Diphenhydramine (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/51/13108?source=see_link\">",
"    see \"Diphenhydramine (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Banophen&trade; Anti-Itch [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Extra Strength Itch Stopping [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Relief Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Stopping Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Stopping [OTC];",
"     </li>",
"     <li>",
"      Dermamycin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benadryl&reg; Cream;",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Relief Stick;",
"     </li>",
"     <li>",
"      Benadryl&reg; Spray",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9923655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8082160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Relief of pain and itching:",
"     </b>",
"     Topical: Apply 1% or 2% to affected area up to 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8082159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/51/13108?source=see_link\">",
"      see \"Diphenhydramine (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Relief of pain and itching:",
"     </b>",
"     Topical: Children &ge;2 years: Apply 1% or 2% to affected area up to 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride: 2% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade; Anti-Itch: 2% (28.4 g) [contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Stopping: 1% (14.2 g, 28.3 g) [contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Stopping Extra Strength: 2% (14.2 g) [contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermamycin&reg;: 2% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Extra Strength Itch Stopping: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Stopping Extra Strength: 2% (59 mL) [contains ethanol; contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermamycin&reg;: 2% (60 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as hydrochloride [stick]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Relief Extra Strength: 2% (14 mL) [contains ethanol; contains zinc acetate 0.1%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel, liquid stick, spray",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8082078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topically for relief of pain and itching associated with insect bites, minor cuts and burns, or rashes due to poison ivy, poison oak, and poison sumac",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DiphenhydrAMINE may be confused with desipramine, dicyclomine, dimenhyDRINATE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benadryl&reg; may be confused with benazepril, Bentyl&reg;, Benylin&reg;, Caladryl&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Institute for Safe Medication Practices (ISMP) has reported cases of patients mistakenly",
"       <i>",
"        swallowing",
"       </i>",
"       Benadryl&reg; Itch Stopping [OTC] gel intended for topical application. Unclear labeling and similar packaging of the topical gel in containers resembling an oral liquid are factors believed to be contributing to the administration errors. The topical gel contains camphor which can be toxic if swallowed. ISMP has requested the manufacturer to make the necessary changes to prevent further confusion.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8082088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8082084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenhydramine or any component of the formulation; neonates or premature infants; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8082085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Topical products should not be used on large areas of the body, or on chicken pox or measles. Healthcare provider should be contacted if topical use is needed for &gt;7 days. Topical products are not for OTC use in children &lt;2 years of age. Do not use with other products containing diphenhydramine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14445923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, diphenhydramine crosses the placenta. Diphenhydramine can also be measurable in the serum following topical administration to large areas of the body. Refer to the diphenhydramine (systemic) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14445925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, diphenhydramine can be detected in breast milk. Diphenhydramine can also be measurable in the serum following topical administration to large areas of the body. Refer to the diphenhydramine (systemic) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Benadryl Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $4.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Banophen External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.1% (28.4 g): $4.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Benadryl Extra Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.1% (28.3 g): $4.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Benadryl Itch Stopping External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-0.1% (28.3 g): $3.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Diphenhydramine-Zinc Acetate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.1% (28 g): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benadryl Anti-Itch Childrens External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45% (85 g): $4.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benadryl Itch Stopping External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (118 mL): $5.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Dermarest External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (19.5 g): $2.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Benadryl Maximum Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 mL): $5.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stick",
"     </b>",
"     (Benadryl Itch Relief External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.1% (14 mL): $2.21",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Stancavage M, Osterhoudt KC, and Henretig FM, \"Caladryl Ingestion: A New Poisoning From a Common Household Product,\"",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):520.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9110 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1269=[""].join("\n");
var outline_f1_15_1269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082068\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082069\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9923655\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082160\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082159\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082187\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082071\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082078\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082066\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082088\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082084\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082085\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082091\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082092\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14445923\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14445925\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322621\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9110|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/33/7705?source=related_link\">",
"      Diphenhydramine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=related_link\">",
"      Diphenhydramine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/48/19207?source=related_link\">",
"      Diphenhydramine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=related_link\">",
"      Diphenhydramine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/51/13108?source=related_link\">",
"      Diphenhydramine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_15_1270="Psychosocial interventions for severe mental illness";
var content_f1_15_1270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychosocial interventions for severe mental illness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Juan Bustillo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Elizabeth Weil, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1270/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/15/1270/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1988153\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe mental illness is a term used to characterize mental disorders with severe symptoms and behavioral impairment, pronounced disability in basic life skills, and a chronic or prolonged course of illness. Patients with these conditions typically have substantial impairments in personal, social and occupational functioning.",
"   </p>",
"   <p>",
"    Assertive community treatment (ACT) and supported employment are psychosocial interventions developed to address functional deficits of patients with severe mental illness. ACT is a high intensity, integrated, community-based model for delivering clinical and other social services to individuals with severe mental illness. Supported employment programs provide support to individuals with severe mental illness to find and maintain a job in the competitive job market. Although their availability varies, these interventions are used to augment pharmacotherapy for severe mental disorders.",
"   </p>",
"   <p>",
"    This topic addresses psychosocial interventions for severe mental illness. Psychosocial interventions specific to individual disorders are discussed separately, as are pharmacologic treatments for these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=see_link\">",
"     \"Psychosocial interventions for schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link\">",
"     \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4105?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Acute treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575180\">",
"    <span class=\"h1\">",
"     SEVERE MENTAL ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than treating a specific mental disorder, assertive community treatment (ACT) and supported employment have been developed to treat patients with a &ldquo;severe mental illness&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/1\">",
"     1",
"    </a>",
"    ], ie, a mental disorder that has each of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe symptoms and behavioral impairment",
"     </li>",
"     <li>",
"      Pronounced disability in basic life skills",
"     </li>",
"     <li>",
"      Prolonged course of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ACT and supported employment have been tested in and are used for patients with schizophrenia, schizoaffective disorder, recurrent bipolar disorder, and chronic or recurrent psychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Certain personality disorders and other psychiatric disorders are sometimes included within the category of severe mental illness. Variation in the disorders included under the term is seen when the designation is used to determine eligibility for mental health care and other social services [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/1\">",
"     1",
"    </a>",
"    ]. Definitions of severe mental illness typically exclude substance abuse and dependence (as primary disorders), dementia, and mental retardation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988568\">",
"    <span class=\"h1\">",
"     ASSERTIVE COMMUNITY TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988576\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe mental illness are often ill-prepared to find and maintain the multiple services they need in order to function in the community, such as housing, clinical care, pharmacy, and transportation. Even with the help of case managers coordinating services for them (eg, scheduling appointments), many patients lack the social and cognitive competence to follow-through, contributing to gaps in treatment and other services, and increasing patients&rsquo; risk of relapse. The goal of assertive community treatment (ACT) programs is to prevent relapse and hospitalization by providing comprehensive, integrated community services. ACT is not typically a psychotherapeutic intervention implemented by an independent clinician, but a set of services usually embedded in a public mental health program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988583\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend ACT for individuals with severe mental illness who have a recent history of repeated hospitalization or homelessness. ACT should also be considered for individuals with severe mental illness who are at risk for hospitalization or homelessness as evidenced by a combination of the factors below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe illness (persistently high symptoms)",
"     </li>",
"     <li>",
"      Poor insight",
"     </li>",
"     <li>",
"      Cognitive impairment",
"     </li>",
"     <li>",
"      Poor compliance",
"     </li>",
"     <li>",
"      Co-morbid substance abuse",
"     </li>",
"     <li>",
"      Limited family and other social support",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988590\">",
"    <span class=\"h2\">",
"     Intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACT is a team-based program that provides clinical and care management services to patients in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/4\">",
"     4",
"    </a>",
"    ]. Patient behaviors targeted by ACT programs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintaining a safe residence in the community",
"     </li>",
"     <li>",
"      Compliance with antipsychotic and other prescribed medications",
"     </li>",
"     <li>",
"      Minimal utilization of (or need for) emergency psychiatric and medical services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To achieve these goals, the ACT model has incorporated numerous specialized features [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multidisciplinary team that includes case managers, a psychiatrist, psychiatric nurse, and occupational therapist, as well as access to a pharmacist, primary care physician, and legal advocate as necessary. Team members meet weekly to discuss patients under their care. ACT teams are based on the principle of shared responsibility for each patient.",
"     </li>",
"     <li>",
"      Team members provide services directly to the patient. Outreach and, if necessary, clinical services are provided in the community. As an example, if the patient does not show up at the clinic for a scheduled medication appointment, a team member would visit the patient where he or she lives. Services are available, as needed, 24 hours per day, seven days a week.",
"     </li>",
"     <li>",
"      The case manager functions as the patient&rsquo;s principal resource. To increase effectiveness, the ACT model specifies a ratio of case managers to patients of 1:12 and continuity of care with the same case manager to the extent feasible. Frequent interactions between the patient and the ACT team are emphasized.",
"     </li>",
"     <li>",
"      The case manager&rsquo;s role varies across patients and their needs over time, but may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bringing medications to the home",
"     </li>",
"     <li>",
"      Taking the patient to appointments",
"     </li>",
"     <li>",
"      Providing skills training in the community (eg, learning to ride the bus) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=see_link&amp;anchor=H13622373#H13622373\">",
"       \"Psychosocial interventions for schizophrenia\", section on 'Social skills training'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients are not typically enrolled in ACT programs for a specific length of time. Continued participation is based on the patient&rsquo;s status. Once he or she demonstrates consistent treatment adherence, the level of care can be gradually decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988597\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of six randomized trials for homeless patients with serious mental illness found ACT led to a 37 percent greater reduction in homelessness and a 26 percent greater improvement in psychiatric symptoms compared to standard case management treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of randomized trials for patients with severe mental illness and a history of repeated hospitalization found that ACT led to a reduction in the number of days hospitalized relative to those receiving standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/6\">",
"     6",
"    </a>",
"    ]. Individuals assigned to ACT used fewer emergency services and more outpatient services, including financial and housing assistance, relative to individuals receiving standard care. ACT appears to be most effective for patients with high rates of hospitalization.",
"   </p>",
"   <p>",
"    Most studies of ACT have failed to find improvement in competitive employment, social functioning, and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/6\">",
"     6",
"    </a>",
"    ]. Tested as a multi-modal intervention, it is not known which elements of ACT are responsible for the reductions in relapse and hospitalization.",
"   </p>",
"   <p>",
"    Since ACT was first defined, a series of similar programs (sometimes collectively referred to as Intensive Case Management) have been developed with differing emphases among the component parts. ACT is by far the best studied model among these programs. &nbsp;Comparative trials of these programs are lacking. However, programs with greater fidelity to the ACT model have achieved lower rates of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988831\">",
"    <span class=\"h1\">",
"     SUPPORTED EMPLOYMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of individuals with severe mental illness, less than 20 percent have been estimated to be competitively employed (ie, to have jobs in the competitive job market) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/8\">",
"     8",
"    </a>",
"    ]. Traditional approaches to vocational rehabilitation in this population have emphasized sheltered employment, such as a job in an entity (eg, a store or a factory) owned by a rehabilitation agency. More recent approaches such as supported employment have emphasized improving patients&rsquo; abilities to find and maintain employment in the competitive job market.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988838\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people with severe mental disorders want to work. Supported employment programs seek to help them find and maintain competitive employment in the community with as much autonomy as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988845\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with severe mental illness who wish to work be provided with supported employment services and the opportunity to maintain competitive employment. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988852\">",
"    <span class=\"h2\">",
"     Intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supported employment interventions vary, but key components include [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Services to support the attainment and maintenance of a permanent, competitive job",
"     </li>",
"     <li>",
"      Job placement based on patient preference, strengths, and work experiences",
"     </li>",
"     <li>",
"      Rapid job search rather than prolonged assessment, preparation, and training",
"     </li>",
"     <li>",
"      Availability of ongoing staff support in finding and maintaining employment (eg, a &ldquo;work coach&rdquo;)",
"     </li>",
"     <li>",
"      Integration of vocational and mental health services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a person with schizophrenia experiencing persistent delusions, hallucinations, poverty of speech and avolition, states when approached that he would like to work in a shoe store. The work coach helps the patient find a store with job openings and assists him with the application. Obtaining support from the store manager, the work coach provides daily on-site training until the patient learns the skills to complete all necessary tasks. Within days, the patient starts working independently with on-site support initially several days per week. Over time, the work coach&rsquo;s role is reduced to contact once or twice per month.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988859\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 18 randomized trials found supported employment to be more effective than pre-vocational training (a more traditional rehabilitative approach) in enabling individuals with severe mental illness to achieve competitive employment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/3\">",
"     3",
"    </a>",
"    ]. At 18 months, more individuals who received supported employment were employed than individuals who received pre-vocational training (34 versus 12 percent), with a need to treat 4.5 patients to yield one with benefit. Individuals in the supported employment group earned more and worked more hours per month compared to the pre-vocational training group.",
"   </p>",
"   <p>",
"    Supported employment programs that incorporate most or all of the key components described above were found to be more effective than those with fewer of the components [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/6\">",
"     6",
"    </a>",
"    ]. Supported employment has not been found to increase stress, exacerbate symptoms, or result in other negative clinical outcomes. Individual components of the supported employment model have not been found to improve employment outcomes, with the exception of integration of vocational services and mental health services, which is associated with increased employment rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1270/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1988852\">",
"     'Intervention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1988964\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assertive community treatment (ACT) and supported employment are psychosocial interventions for individuals with severe mental illness, ie, mental disorders characterized by severe symptoms and behavioral impairment, pronounced disability in basic life skills, and a prolonged course of illness. (See",
"      <a class=\"local\" href=\"#H575180\">",
"       'Severe mental illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACT is a high intensity, integrated, community-based model for delivering clinical and other social services to individuals with severe mental illness. Its goals are to enable patients to maintain a community based residence, adhere to prescribed medications, and have minimal utilization of emergency or inpatient services. Features of the ACT model include (see",
"      <a class=\"local\" href=\"#H1988590\">",
"       'Intervention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A multidisciplinary team-based approach",
"     </li>",
"     <li>",
"      Assertive outreach to patients in their communities",
"     </li>",
"     <li>",
"      Direct provision of clinical and other social services &nbsp;",
"     </li>",
"     <li>",
"      Case managers with limited caseloads, ie, a ratio of case managers to patients of 1:12",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals with severe mental illness who have a recent history of repeated hospitalization or homelessness, we recommend ACT over non-intensive case management or no case management (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). ACT should also be considered for individuals with severe mental illness who are at high risk for hospitalization or homelessness, such as patients with cognitive impairment, poor medication adherence or comorbid substance abuse. (See",
"      <a class=\"local\" href=\"#H1988583\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1988597\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supported employment programs provide support to individuals with severe mental illness to find and maintain a job in the competitive job market. Characteristics of these programs include (see",
"      <a class=\"local\" href=\"#H1988590\">",
"       'Intervention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Job placement based on patient preference, strengths, and work experiences",
"     </li>",
"     <li>",
"      Rapid job search rather than prolonged assessment, preparation, and training",
"     </li>",
"     <li>",
"      Availability of ongoing staff support (eg, a &ldquo;work coach&rdquo;)",
"     </li>",
"     <li>",
"      Integration of vocational and mental health services",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with severe mental illness who are not employed but wish to work be provided with supported employment services rather than traditional vocational rehabilitation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1988845\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1988859\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/1\">",
"      Schinnar AP, Rothbard AB, Kanter R, Jung YS. An empirical literature review of definitions of severe and persistent mental illness. Am J Psychiatry 1990; 147:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/2\">",
"      Dieterich M, Irving CB, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database Syst Rev 2010; :CD007906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/3\">",
"      Crowther R, Marshall M, Bond G, Huxley P. Vocational rehabilitation for people with severe mental illness. Cochrane Database Syst Rev 2001; :CD003080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/4\">",
"      Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. Schizophr Bull 1998; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/5\">",
"      Coldwell CM, Bender WS. The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. Am J Psychiatry 2007; 164:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/6\">",
"      Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010; 36:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/7\">",
"      Teague GB, Bond GR, Drake RE. Program fidelity in assertive community treatment: development and use of a measure. Am J Orthopsychiatry 1998; 68:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/8\">",
"      Lehman AF. Vocational rehabilitation in schizophrenia. Schizophr Bull 1995; 21:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/9\">",
"      Bond GR. Supported employment: evidence for an evidence-based practice. Psychiatr Rehabil J 2004; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1270/abstract/10\">",
"      Bond GR, Drake RE, Mueser KT, Becker DR. An update on supported employment for people with severe mental illness. Psychiatr Serv 1997; 48:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16590 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1270=[""].join("\n");
var outline_f1_15_1270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1988964\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1988153\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H575180\">",
"      SEVERE MENTAL ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1988568\">",
"      ASSERTIVE COMMUNITY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988576\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988583\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988590\">",
"      Intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988597\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1988831\">",
"      SUPPORTED EMPLOYMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988838\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988845\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988852\">",
"      Intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1988859\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1988964\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=related_link\">",
"      Psychosocial interventions for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4105?source=related_link\">",
"      Unipolar major depression with psychotic features: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=related_link\">",
"      Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_15_1271="Natalizumab: Drug information";
var content_f1_15_1271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Natalizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/10/7333?source=see_link\">",
"    see \"Natalizumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13735354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Risk Factor Identified for Progressive Multifocal Leukoencephalopathy Associated with Natalizumab",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is alerting clinicians and the public to a newly identified risk factor for the development of progressive multifocal leukoencephalopathy (PML) associated with natalizumab (Tysabri&reg;). A positive test result for anti-JC virus (JCV) antibodies is a risk factor for the development of PML. Additional risk factors include a longer duration of treatment (especially &gt;2 years) and a history of immunosuppressant medication use (eg, mitoxantrone, azathioprine, methotrexate, cyclophosphamide or mycophenolate mofetil). Patients demonstrating all three risk factors have an estimated PML risk of 11/1000. As of January 4, 2012, the FDA is aware of 201 confirmed worldwide cases of PML among ~96,582 patients related to the use of natalizumab.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Anti-JCV antibody status is determined by performing an anti-JCV antibody detection test (eg, Stratify JCV Antibody ELISA test); a positive result indicates prior exposure to JCV. Consider testing prior to natalizumab treatment (or during treatment if status is unknown). When assessing the risk for PML using anti-JCV antibody status, a positive test at any time is considered a risk factor regardless of prior or future test results. The risks and benefits of continued natalizumab treatment should be weighed in a patient with a history of a positive anti-JCV antibody test. Patients with a negative result may still be at risk for PML as new JCV infection or false negative result are possible; periodic retesting may be warranted.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Natalizumab treatment should be discontinued immediately at the first sign or symptom of PML (eg, progressive weakness on one side of the body, limb clumsiness, visual disturbance, changes in thinking, memory, personality or orientation). Patients should be counseled to contact their prescriber if symptoms occur. Adverse events should be reported to the FDA through the MedWatch program.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information refer to",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm288186.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm288186.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tysabri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5594359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tysabri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Monoclonal Antibody, Selective Adhesion-Molecule Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis:",
"     </b>",
"     I.V.: 300 mg infused over 1 hour every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Crohn's disease:",
"     </b>",
"     I.V.: 300 mg infused over 1 hour every 4 weeks; discontinue if therapeutic benefit is not observed within initial 12 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Concomitant use with corticosteroids:",
"     </i>",
"     For patients who begin treatment while on chronic oral corticosteroids, begin tapering oral steroids when the onset of natalizumab therapeutic benefit is observed; discontinue use if patient cannot be tapered off of oral corticosteroids within 6 months of therapy initiation. If additional concomitant corticosteroids are required and exceed 3 months/year (in addition to initial corticosteroid taper), consider discontinuing therapy.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F200031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F200032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Discontinue use with jaundice or signs/symptoms of hepatic injury.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tysabri&reg;: 300 mg/15 mL (15 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      U.S.:",
"     </b>",
"     Tysabri&reg; is deemed to have an approved REMS program. As a requirement of the REMS program, access to this medication is restricted. Patients must be enrolled in the Tysabri&reg; Outreach Unified Commitment to Health (TOUCH&trade;) Prescribing Program (800-456-2255) to receive natalizumab (MS-TOUCH&trade; for multiple sclerosis or CD-TOUCH&trade; for Crohn&rsquo;s disease). Healthcare providers must also register with the program in order to prescribe, dispense or administer natalizumab. Treatment must be reauthorized every 6 months. Natalizumab is available only through infusion centers registered with the TOUCH&trade; program; infusion center information is available at 1-800-456-2255.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Canada:",
"     </b>",
"     Patients receiving natalizumab therapy for multiple sclerosis are to be enrolled in the Tysabri Care Program&trade; (888-827-2827). This program is associated with the prescribing, administration, and monitoring of Canadian patients receiving natalizumab. Clinicians are educated on the appropriate use of natalizumab and are expected to discuss the benefits/risks of therapy. Clinicians should evaluate patients every 6 months during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7885623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089809.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089809.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Warm solution to room temperature prior to administration. Diluted solution should be infused over 1 hour; do not administer by I.V. bolus or push. Patients should be closely monitored for signs and symptoms of hypersensitivity during the infusion and for at least 1 hour after the infusion is complete. The infusion should be discontinued if a reaction occurs, and treatment of the reaction should be instituted. Following infusion, flush line with NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monotherapy for the treatment of relapsing forms of multiple sclerosis; treatment of moderately- to severely-active Crohn&rsquo;s disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canada labeling: Treatment of relapsing forms of multiple sclerosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (32% to 38%), fatigue (10% to 27%), depression (&le;19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&le;17%), gastroenteritis (&le;11%), abdominal discomfort (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3% to 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (8% to 19%), extremity pain (16%), back pain (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (&le;22%), lower respiratory infection (&le;17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infusion-related reaction (11% to 24%), influenza (&le;12%), flu-like syndrome (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (5% to 6%), chest discomfort (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Vertigo (&le;6%), dysesthesia (3%), syncope (&le;2%), somnolence (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (&le;7%), pruritus (&le;4%), urticaria (&le;2%), dry skin (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (2% to 6%), menstrual irregularities (&le;5%), amenorrhea (&le;2%), ovarian cyst (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (10%), dyspepsia (&le;5%), abdominal pain (&le;4%), constipation (&le;4%), flatulence (&le;3%), aphthous stomatitis (&le;2%), weight changes (&le;2%), cholelithiasis (&le;1%), gingival infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis/vaginal infections (4% to 10%), urinary frequency (&le;9%), urinary incontinence (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematoma (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminase increased (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Bleeding at injection site (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramp (&le;5%), tremor (1% to 3%), rigors (&le;3%), joint swelling (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (&le;8%), cough (&le;7%), tonsillitis (&le;7%), pharyngolaryngeal pain (&le;6%), epistaxis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (9% to 10%), tooth infection (&le;9%), herpes infection (&le;8%), viral infection (&le;7%), hypersensitivity reactions (acute: 2% to 4%; serious acute: &le;1%; delayed: &le;5%), toothache (&le;4%), serious infection (2% to 3%), night sweats (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acne, agitation, anaphylaxis/anaphylactoid reactions, anemia, angina, appendicitis, bilirubin increased, bronchopulmonary aspergillosis,",
"     <i>",
"      Burkholderia cepacia",
"     </i>",
"     , Crohn&rsquo;s disease exacerbation, cryptosporidial gastroenteritis, cytomegalovirus hepatitis, dizziness, dyspnea, erythema. fever, flushing, hemoglobin decreased (mild, transient), hepatotoxicity, herpes encephalitis, herpes meningitis, hypotension, IRIS, joint stiffness, lethargy, leukocytosis, nasopharyngitis, opportunistic infections (including progressive multifocal leukoencephalopathy [PML], meningitis, and bronchopulmonary infections), muscle spasms, muscle weakness, onychorrhexis, paresis, pericarditis (case report), petechiae, pharyngitis,",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia, pneumonia, psychomotor hyperactivity, pulmonary",
"     <i>",
"      Mycobacterium avium intracellulare",
"     </i>",
"     , suicidal ideation, tachycardia, thrombocytopenia, thrombophlebitis, varicella pneumonia, vasodilatation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to natalizumab, murine proteins, or any component of the formulation; current or history of progressive multifocal leukoencephalopathy (PML)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canada labeling: Additional contraindications (not in U.S. labeling): Immunocompromised patients as a result of immunosuppressant or antineoplastic therapy, or immunodeficiencies (eg, HIV, leukemia, lymphoma)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Hepatotoxicity, including transaminase and bilirubin elevation, has been reported with use; may occur as early as 6 days after the first dose; may recur with treatment rechallenge; discontinue use with jaundice or signs/symptoms of hepatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/infusion-related reactions: During clinical studies, up to 24% of patients experienced an infusion-related reaction; serious systemic hypersensitivity reactions occurred in &le;1% of patients. Severe reactions, including anaphylaxis, may occur rarely. Patients treated with brief initial courses of therapy (&le;3 infusions) followed by an extended interruption in therapy (&ge;3 months) may be at an increased risk for hypersensitivity reactions following reinitiation of therapy. Retreatment is not recommended in patients developing hypersensitivity reactions. Infusion-related reactions may occur more frequently in patients with antibodies to natalizumab. Antibody formation (which occurs in about 10% of patients) is associated with a decrease in natalizumab levels and a decrease in the efficacy of natalizumab. Antibody testing should be performed in any patient when there is a suspicion of persistent antibodies and should be considered in patients that resume therapy following a period of  dosage interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution inflammatory syndrome (IRIS): IRIS has been reported in patients after discontinuing natalizumab due to PML. In most cases, this occurred after plasma exchange was used in an attempt to remove natalizumab. IRIS is a rare condition which is characterized by severe inflammation during or following immune system recovery, which can result in a decline in patient condition, including neurological symptoms and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: Use may be associated with an increased risk of infections, including opportunistic infections and serious herpes infections (rare, postmarketing reports; concurrent use of antineoplastic, immunosuppressant [including short-course corticosteroids], or immunomodulating agents may increase this risk). In the presence of a serious  herpes infection, discontinue therapy until successful resolution of the infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Progressive multifocal leukoencephalopathy:",
"     <b>",
"      [U.S. Boxed Warning]: Increased risk of developing fatal or disabling progressive multifocal leukoencephalopathy (PML, an opportunistic infection caused by the JC virus); patients must be routinely monitored for signs of PML with baseline and periodic MRI evaluations; access to and provision of therapy requires registration of patients and healthcare providers with the TOUCH&trade; prescribing program. Risk factors for the development of PML include:",
"     </b>",
"     Recent or concurrent immunomodulator therapy or prior or concurrent immunosuppressant therapy (PML has also been reported with natalizumab monotherapy); prolonged duration of treatment (especially &gt;2 years); positive test result for anti-JC virus (JCV) antibodies. Anti-JCV antibody testing prior to or during treatment may be considered; testing should not be used to diagnose PML and should not be performed for at least 2 weeks after plasma exchange. A brain MRI scan (baseline) should be obtained prior to initiating therapy in MS patients and should be considered in Crohn&rsquo;s patients. Therapy must be immediately withheld in any patient with any sign or symptom suggestive of PML. Use should generally be avoided in patients who are significantly immunocompromised or receiving chronic immunosuppressant or immunomodulatory therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Crohn&rsquo;s disease: Natalizumab should not be used in combination with immunosuppressants or tumor necrosis factor (TNF) inhibitors in patients with Crohn&rsquo;s disease; aminosalicylates may be used concurrently with natalizumab. For patients who begin treatment while on chronic oral corticosteroids, begin tapering oral steroids when the onset of natalizumab therapeutic benefit is observed; discontinue use if patient cannot be tapered off of oral corticosteroids within 6 months of therapy initiation. If additional concomitant corticosteroids are required and exceed 3 months/year (in addition to initial corticosteroid taper), consider discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with a history of depression; closely monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use should be restricted to patients with inadequate response to or intolerant of other therapies for Crohn&rsquo;s disease or multiple sclerosis. Carefully evaluate the overall benefit to risk in patients that develop persistent antibodies to natalizumab.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term therapy: Safety and efficacy have not been established for therapy &gt;2 years or in chronic progressive multiple sclerosis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F200018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Pregnant women exposed to natalizumab should be enrolled in the Tysabri&reg; Pregnancy Exposure Registry (800-456-2255).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F200019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Natalizumab is excreted in human milk; however, the effects on infants are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Tysabri Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/15 mL (15 mL): $4841.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for symptoms of hepatotoxicity (eg, elevated serum transaminases, bilirubin); hypersensitivity reactions during, and for 1 hour after, infusion; symptoms of persistent antibody-positivity (eg, anxiety, dizziness, dyspnea, feeling cold, flushing,  headache, hypertension, myalgia, nausea, pruritus, pyrexia, rigors, tachycardia, tremor, urticaria or, vomiting). Antibody testing is recommended if persistent antibodies are suspected and repeated in 3 months in all patients with documented positivity on initial test. Consider antibody testing in patients that resume therapy following a period of dosage interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Baseline brain MRI scan; if PML is suspected, obtain gadolinium-enhanced brain MRI scan and CSF analysis for JC viral DNA. Evaluate for signs or symptoms of progressive multifocal leukoencephalopathy (focal neurologic deficits, which may present as hemiparesis, visual field deficits, cognitive impairment, aphasia, ataxia, and/or cranial nerve deficits) at 3 and 6 months after first infusion; every 6 months thereafter.",
"     <b>",
"      Note:",
"     </b>",
"     Transient and reversible leukocytosis (excluding neutrophils) and mildly reduced hemoglobin may occur with treatment and may require ~4 months for return to baseline values after the last dose; anti-JCV antibody (prior to therapy and periodically during therapy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tysabri (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Natalizumab is a monoclonal antibody against the alpha-4 subunit of integrin molecules. These molecules are important to adhesion and migration of cells from the vasculature into inflamed tissue. Natalizumab blocks integrin association with vascular receptors, limiting adhesion and transmigration of leukocytes. Efficacy in specific disorders may be related to reduction in specific inflammatory cell populations in target tissues. In multiple sclerosis, efficacy may be related to blockade of T-lymphocyte migration into the central nervous system; treatment results in a decreased frequency of relapse. In Crohn&rsquo;s disease, natalizumab decreases inflammation by binding to alpha-4 integrin, blocking adhesion and migration of leukocytes in the gut.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crohn&rsquo;s disease: 2.4-8 L; Multiple sclerosis: 3.8-7.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Crohn&rsquo;s disease: 3-17 days; Multiple sclerosis: 7-15 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bloomgren G, Richman S, Hotermans C, et al, &ldquo;Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(20):1870-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/22591293/pubmed\" id=\"22591293\" target=\"_blank\">",
"        22591293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghosh S, Goldin E, Gordon FH, et al, &ldquo;Natalizumab for Active Crohn's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(1):24-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/12510039/pubmed\" id=\"12510039\" target=\"_blank\">",
"        12510039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koralnik IJ, &ldquo;New Insights Into Progressive Multifocal Leukoencephalopathy,&rdquo;",
"      <i>",
"       Curr Opin Neurol",
"      </i>",
"      , 2004, 17(3):365-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/15167073/pubmed\" id=\"15167073\" target=\"_blank\">",
"        15167073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polman CH, O&rsquo;Connor PW, Havrdova E, et al, &ldquo;A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354:899-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/16510744/pubmed\" id=\"16510744\" target=\"_blank\">",
"        16510744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudick RA, Stuart WH, Calabresi PA et al, &ldquo;Natalizumab Plus Interferon Beta-1a for Relapsing Multiple Sclerosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354:911-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/16510745/pubmed\" id=\"16510745\" target=\"_blank\">",
"        16510745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandborn WJ, Colombel JF, Enns R, et al, &ldquo;Natalizumab Induction and Maintenance Therapy for Crohn's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(18):1912-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/16267322/pubmed\" id=\"16267322\" target=\"_blank\">",
"        16267322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Targan SR, Feagan BG, Fedorak RN, et al, &ldquo;Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2007, 132(5):1672-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/17484865/pubmed\" id=\"17484865\" target=\"_blank\">",
"        17484865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Assche G, Van Ranst M, Sciot R, et al, &ldquo;Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(4):362-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1271/abstract-text/15947080/pubmed\" id=\"15947080\" target=\"_blank\">",
"        15947080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yousry TA, Major EO, Ryschkewitsch C et al, &ldquo;Evaluation of Patients Treated With Natalizumab for Progressive Multifocal Leukoencephalopathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      2006, 354:924-33.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10252 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1271=[""].join("\n");
var outline_f1_15_1271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13735354\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709166\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5594359\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200046\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200029\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200030\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200031\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200032\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200011\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199999\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234120\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885623\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200013\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200012\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200044\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200016\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200001\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299746\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200005\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200007\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200018\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200035\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200019\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323460\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200009\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539898\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200000\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200015\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10252\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10252|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/10/7333?source=related_link\">",
"      Natalizumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_15_1272="Pegylated interferon (peginterferon) alfa-2a and ribavirin: Drug information";
var content_f1_15_1272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2a and ribavirin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/16/44294?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2a and ribavirin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9491710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys&reg; RBV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9491713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13503087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canadian Consensus Guidelines recommend peginterferon plus ribavirin as treatment of choice for chronic hepatitis C (Sherman, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic hepatitis C (HCV) monoinfection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genotypes 1,4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;75 kg: Peginterferon alfa-2a (SubQ): 180 mcg/once weekly",
"     <b>",
"      and",
"     </b>",
"     ribavirin (oral) 1000 mg/day (divided into 2 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;75 kg: Peginterferon alfa-2a (SubQ): 180 mcg/once weekly",
"     <b>",
"      and",
"     </b>",
"     ribavirin (oral) 1200 mg/day (divided into 2 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genotypes 2,3: Peginterferon alfa-2a (SubQ): 180 mcg/once weekly",
"     <b>",
"      and",
"     </b>",
"     ribavirin (oral) 800 mg/day (divided into 2 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV-HCV coinfection:",
"     </b>",
"     HCV genotypes 1,2,3,4: Peginterferon alfa-2a (SubQ): 180 mcg/once weekly",
"     <b>",
"      and",
"     </b>",
"     ribavirin (oral) 800 mg/day (divided into 2 doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment duration",
"     </b>",
"     (Canadian Consensus Guidelines [Sherman, 2007]):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      HCV genotype 1:",
"     </i>",
"     Treatment recommended for 48 weeks or may consider extended therapy up to 72 weeks in slow responders; may reduce treatment to 24 weeks in patients achieving RVR at 4 weeks",
"     <b>",
"      AND",
"     </b>",
"     without poor response predictors (eg, high viral load, advanced fibrosis, elderly); discontinue therapy in patients failing to achieve EVR at 12 weeks or with detectable HCV RNA at 24 weeks; retreatment for 48 weeks is required in patients who relapse after discontinuing abbreviated therapy (24 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      HCV genotypes 2,3:",
"     </i>",
"     Treatment recommended for 24 weeks; may consider abbreviated therapy (12 or 16 weeks) in patients with weight-based ribavirin dosing and RVR; if relapse occurs following abbreviated therapy, retreat for 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      HCV genotype 4,5, and 6:",
"     </i>",
"     Treatment recommended for 48 weeks; discontinue therapy in patients failing to achieve EVR at 12 weeks or with detectable HCV RNA at 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      HCV-HIV coinfection:",
"     </i>",
"     Treatment recommended for 48 weeks; discontinue therapy in patients failing to achieve EVR at 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Relapsing or nonresponding patients (regardless of genotype):",
"     </i>",
"     Peginterferon/ribavirin therapy may be considered in patients that have relapsed or were nonresponsive to prior interferon monotherapy or interferon/ribavirin combination therapy; discontinue therapy if EVR not achieved after 12 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9494669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9493369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2a: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;20 mL/minute: No dosage adjustment required. Monitor closely as dose reduction may be warranted with onset of adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     End-stage renal disease requiring hemodialysis: Reduce initial dosage to 135 mcg/once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ribavirin: Oral: Use is not recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9493370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Avoid use in decompensated hepatic disease (eg, Child-Pugh class B or C). Use is contraindicated in HCV-HIV coinfected patients with cirrhosis and baseline Child-Pugh score &ge;6.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2a: SubQ: Reduce dose to 90 mcg/once weekly in the presence of progressive ALT increases greater than baseline. Therapy discontinuation may be necessary for persistently marked ALT elevations despite dose reduction and/or with accompanying elevated bilirubin or with evidence of hepatic decompensation.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9493368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations (per manufacturer labeling - also refer to dosing in renal and hepatic impairment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adverse events/toxicity:",
"     </b>",
"     For moderate-to-severe adverse reactions (clinical and/or laboratory): Reduce peginterferon alfa-2a dose to 135 mcg/once weekly; may need decreased to 90 mcg/once weekly in some cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild depression: No dosage adjustment required; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate depression: Decrease peginterferon alfa-2a dose to 90-135 mcg/once weekly; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe depression: Discontinue combination therapy; obtain immediate psychiatric consultation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemoglobin (patients without cardiac disease):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL: Decrease ribavirin dose to 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL: Discontinue ribavirin; upon resolution of decreased hemoglobin, may reinitiate ribavirin therapy at 600 mg/day with subsequent increase to 800 mg/day as tolerated; higher doses are not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemoglobin (patients with stable cardiac disease):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin decrease &gt;2 g/dL in any 4-week period: Permanently decrease ribavirin dose to 600 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;12 g/dL after ribavirin dose is decreased for 4 weeks: Discontinue ribavirin; upon resolution of decreased hemoglobin, may reinitiate ribavirin therapy at 600 mg/day with subsequent increase to 800 mg/day as tolerated; higher doses are not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neutrophils:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrophils &lt;0.75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2a dose to 135 mcg/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrophils &lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Interrupt peginterferon alfa-2a therapy; may reinitiate therapy at 90 mcg/week when ANC &gt;1 x  10",
"     <sup>",
"      9",
"     </sup>",
"     /L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Platelets:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Decrease peginterferon alfa-2a dose to 90 mcg/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Permanently discontinue peginterferon alfa-2a and ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9493424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Combination package:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pegasys RBV&reg; [1-week package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (1s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (35s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (1s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (42s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (1s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Pegasys RBV&reg; [1-week package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/mL (1 mL) (1s) [contains polysorbate 80, benzyl alcohol; single-use vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (35s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/mL (1 mL) (1s) [contains polysorbate 80, benzyl alcohol; single-use vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (42s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/mL (1 mL) (1s) [contains polysorbate 80, benzyl alcohol; single-use vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Pegasys RBV&reg; [4-week package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (112s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (4s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (140s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (4s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (168s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (4s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (168s + 28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/0.5 mL (0.5 mL) (4s) [contains polysorbate 80, benzyl alcohol; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Pegasys RBV&reg; [4-week package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (112s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/mL (1 mL) (4s) [contains polysorbate 80, benzyl alcohol; single-use vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (140s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/mL (1 mL) (4s) [contains polysorbate 80, benzyl alcohol; single-use vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral: Ribavirin 200 mg (168s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Injection, solution: Peginterferon alfa-2a: 180 mcg/mL (1 mL) (4s) [contains polysorbate 80, benzyl alcohol; single-use vial]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9493374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9491715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy for the treatment of chronic hepatitis C (HCV) in patients without cirrhosis and patients with compensated cirrhosis; includes patients coinfected with stable HIV disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9491866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions as reported with use of the combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (40% to 49%), headache (35% to 48%), fever (37% to 41%), insomnia (19% to 32%), rigors (16% to 30%), irritability (15% to 28%), depression (17% to 22%), dizziness (7% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (10% to 25%), pruritus (4% to 25%), dermatitis (1% to 16%), dry skin (4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (24% to 29%), anorexia (20% to 27%), diarrhea (14% to 16%), weight loss (2% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemolytic anemia (&le;14%), neutropenia (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (10% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (32% to 42%), weakness (15% to 26%), arthralgia (16% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (3% to 13%), dyspnea (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (&ge;1% to &le;5%), flushing (&ge;1% to &le;5%), hypertension (&ge;1% to &le;5%), palpitation (&ge;1% to &le;5%), peripheral edema (&ge;1% to &le;5%), syncope (&ge;1% to &le;5%), tachycardia (&ge;1% to &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Pain (6% to 10%), impaired concentration (2% to 10%), anxiety (8%), mood altered (&le;8%), malaise (3% to 6%), emotional disorder (&le;5%), aggression (&ge;1% to &le;5%), confusion (&ge;1% to &le;5%), hyper-/hypoesthesia (&ge;1% to &le;5%), lethargy (&ge;1% to &le;5%), migraine (&ge;1% to &le;5%), nightmares (&ge;1% to &le;5%), somnolence (&ge;1% to &le;5%), suicidal ideation (&ge;1% to &le;5%), vertigo (&ge;1% to &le;5%),  impaired memory (1% to 5%), nervousness (&le;3%), affect lability (HIV-HCV coinfection: &ge;1% to &le;3%), apathy (HIV-HCV coinfection: &ge;1% to &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (5% to 9%), eczema (&ge;1% to &le;5%), photosensitivity (&ge;1% to &le;5%), psoriasis (&ge;1% to &le;5%), urticaria (&ge;1% to &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Libido decreased (2% to 5%), dehydration (&ge;1% to &le;5%), hot flashes (&ge;1% to &le;5%), hyperthyroidism (&ge;1% to &le;5%), impotence (&ge;1% to &le;5%), hypothyroidism (&le;4%), lactic acidosis (HIV-HCV coinfection: &ge;1% to &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (7% to 10%), vomiting (7% to 8%), xerostomia (5% to 8%), appetite decreased (&le;7%), dyspepsia (2% to 6%), constipation (&ge;1% to &le;5%), dysphagia (&ge;1% to &le;5%), flatulence (&ge;1% to &le;5%), glossitis (&ge;1% to &le;5%), mouth ulceration (&ge;1% to &le;5%), stomatitis (&ge;1% to &le;5%), taste disturbance (&ge;1% to &le;5%), cheilitis (HIV-HCV coinfection: &ge;1% to &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Chromaturia (HIV-HCV coinfection: &ge;1% to &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (&ge;1% to 8%), bleeding (gingival) (&ge;1% to &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (3% to 5%), arthritis (&ge;1% to &le;5%), bone pain (&ge;1% to &le;5%), muscle cramps (&ge;1% to &le;5%), muscle weakness (&ge;1% to &le;5%), musculoskeletal pain (&ge;1% to &le;5%), neck pain (&ge;1% to &le;5%), paresthesia (&ge;1% to &le;5%), tremor (&ge;1% to &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eye inflammation (&ge;1% to &le;5%), eye pain (&ge;1% to &le;5%), vision blurred (&ge;1% to &le;5%), xerophthalmia (&ge;1% to &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Earache (&ge;1% to &le;5%), tinnitus (&ge;1% to &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (&ge;1% to &le;5%), epistaxis (&ge;1% to &le;5%), nasal congestion (&ge;1% to &le;5%), nasopharyngitis (&ge;1% to &le;5%), pharyngolaryngeal pain (&ge;1% to &le;5%), rhinitis (&ge;1% to &le;5%), sinus congestion (&ge;1% to &le;5%), throat sore (&ge;1% to &le;5%), upper respiratory infection (&ge;1% to &le;5%), pneumonia (HIV-HCV coinfection: &ge;1% to &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Diaphoresis (2% to 5%), flu-like syndrome (&ge;1% to &le;5%), herpes simplex (&ge;1% to &le;5%), lymphadenopathy (&ge;1% to &le;5%), night sweats (&ge;1% to &le;5%), oral candidiasis (&ge;1% to &le;5%), thirst (&ge;1% to &le;5%), acquired lipodystrophy (HIV-HCV coinfection: &ge;1% to &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening; reported with other interferon preparations and/or ribavirin): Acute hypersensitivity reactions, ALT increased, anaphylaxis, angioedema, aplastic anemia (rare), arrhythmia, atrial fibrillation, bacterial infection (including sepsis), bilirubin (indirect) increased, bronchoconstriction, cardiac ischemia, cardiomyopathy, cerebrovascular hemorrhage, cerebrovascular ischemia, CHF, cholangitis, colitis (ischemic, ulcerative), coma, corneal ulcer, cotton wool spots, deafness (rare), dental disorders, diabetes, encephalopathy, endocarditis, erythema multiforme, facial palsy, fatty liver, fungal infection, GI bleed, gout, hallucination, hepatic dysfunction, hepatic neoplasm (malignant), hepatitis, hepatotoxic reactions, hypotension, hyper-/hypoglycemia, hypertriglyceridemia, injection site necrosis, interstitial nephritis, interstitial pneumonitis, leukopenia, macular edema, MI, myositis, nephrotic syndrome, obtundation, optic neuritis, pancreatitis, pancytopenia, panic attack, papilledema, peptic ulcer, periodontal disorder, peripheral neuropathy, pericarditis, psychotic disorder, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, renal failure, renal insufficiency, retinal detachment, retinal hemorrhages, retinal artery or vein obstruction, rhabdomyolysis, sarcoidosis (including exacerbation), seizures, severe psychiatric reactions, Stevens-Johnson syndrome, suicide, suicidal behavior, thyroiditis, toxic epidermal necrolysis, thrombotic thrombocytopenic purpura, uric acid increased, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Use of alfa interferons has been associated with rare cases of autoimmune diseases, including idiopathic thrombocytopenic purpura, thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis, and Vogt-Koyanagi-Harada syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9491719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alfa interferons, ribavirin,",
"     <i>",
"      E. coli",
"     </i>",
"     -derived products, polyethylene glycol (PEG), or any component of the formulation; decompensated cirrhosis; autoimmune hepatitis or history of autoimmune disease; HCV-HIV coinfection with cirrhosis and baseline Child-Pugh score &ge;6; hemoglobinopathies; history of or pre-existing severe psychiatric disorder; uncontrolled thyroid dysfunction; neonates and infants; males with a pregnant female partner; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9491720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Anemia and severe cytopenias have been observed in patients receiving interferon/ribavirin combination. Rarely, aplastic anemia has been observed with alfa interferon therapy. Use with caution in patients with low peripheral blood counts or myelosuppression, including concurrent use of myelosuppressive therapy. Reduce dose with decreased neutrophil or platelet count and discontinue therapy if significant decreases in neutrophil (&lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L) or platelet counts (&lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebrovascular events (ischemic and hemorrhagic) have been observed in patients receiving alfa interferon therapy, including patients without risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause CNS depression (somnolence, fatigue), which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis: Serious cases of ischemic/hemorrhagic colitis have been observed within 12 weeks of initiating alfa interferon therapy; ulcerative colitis has been reported with use as well; discontinue therapy in suspected/confirmed colitis; upon discontinuation of therapy, resolution of colitis is usually observed within 1-3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydration: Maintain adequate hydration; hypotension associated with dehydration has been observed with use alfa interferons.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental/periodontal disorders: Have been reported with ribavirin and peginterferon therapy; patients should be instructed to brush teeth twice daily and have regular dental exams.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Interferon therapy is associated with immune-mediated reactions including erythema multiforme, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Hemolytic anemia is a significant toxicity, usually occurring within 1-2 weeks, and may worsen underlying cardiac disease; use caution and assess cardiac disease before initiation; avoid use in patients with history of significant or unstable cardiac disease. Patients with renal dysfunction should be carefully assessed for development of anemia. If any deterioration in cardiovascular status occurs, discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Rare cases of acute hypersensitivity (eg, anaphylaxis, angioedema, bronchoconstriction) have been rarely observed with alfa-interferon therapy. Discontinue therapy immediately with signs of hypersensitivity and treat appropriately. Presence of transient rashes may not warrant treatment interruption in the absence of more severe reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertriglyceridemia: Elevated triglyceride levels have been associated with alfa interferon therapy; monitor lipids with therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders: Use in patients with pre-existing or history of severe psychiatric disorders is contraindicated. May cause severe psychiatric adverse events (depression, suicidal behavior/ideation, aggression) in patients with and without previous psychiatric symptoms. Careful neuropsychiatric monitoring is required during therapy. Discontinue therapy with persistent and severe psychiatric symptoms and obtain psychiatric consult.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Ophthalmologic disorders (including retinal hemorrhages, cotton wool spots, and retinal artery or vein obstruction) have occurred rarely in patients using peginterferon alfa-2a. Prior to start of therapy, visual exams are recommended for all patients and periodically during therapy for patients at risk for retinopathy (eg, diabetes mellitus, hypertension). Consider discontinuation of therapy with new or worsening ophthalmologic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Otic effects: Very rare cases of deafness have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Interrupt therapy for symptoms/signs suggestive of pancreatitis. Discontinue therapy with confirmed pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease: Use is contraindicated in patients with a history of autoimmune disease; thyroiditis, immune thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis have been reported with interferon therapy; consider therapy discontinuation with appearance of psoriatic lesions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use peginterferon alfa-2a with caution in patients with cardiac disease, hypertension or arrhythmias; avoid use in patients with unstable or severe cardiac disease within previous 6 months; discontinuation of therapy may be indicated with worsening cardiovascular status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disorders: Use with caution in patients with endocrine disorders; hyper-/hypothyroid have been observed with use of peginterferon alfa-2a; obtain thyroid stimulating hormone (TSH) levels if symptomatic; avoid initiating therapy or discontinue existing therapy with uncontrolled TSH levels; diabetes mellitus and hypo/hyperglycemia have been observed with use; monitor glucose; dosage adjustments of antidiabetic therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use in decompensated hepatic disease or in (HIV/HCV) coinfection with cirrhosis and baseline Child-Pugh score &ge;6 is contraindicated; use with caution in patients with mild-to-moderate hepatic impairment and monitor closely; discontinue treatment with worsening hepatic function or signs/symptoms of hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: Safety and efficacy have not been established in patients with concurrent hepatitis B virus infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Safety and efficacy have not been established in patients with concurrent HIV infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious disorders: Interferon therapy may cause or aggravate fatal or life-threatening infectious disorders; discontinue if signs and symptoms occur. Investigate the etiology of any persistent fever during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Renal impairment: Evaluate renal function prior to initiating therapy; use with caution in patients with renal impairment and only if considered essential; avoid use with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute; monitor for signs/symptoms of toxicity (therapy discontinuation may be required if toxicity occurs).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Avoid use in patients with chronic obstructive pulmonary disease (COPD); use caution in other pulmonary disease; dyspnea, pneumonia, pulmonary infiltrates, sarcoidosis exacerbation have been reported with use. Obtain chest X-ray with onset of fever, dyspnea, cough, or other symptoms; discontinue treatment with persistent/unexplained pulmonary function impairment or pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; evaluate renal function before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Organ transplant recipients: Safety and efficacy have not been established in organ transplant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Use during pregnancy is contraindicated; avoid pregnancy in female patients and female partners of male patients during ribavirin therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure. Negative pregnancy test is required before initiation and monthly thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variability:",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferons.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Safety and efficacy have not been established in patients who have failed other alfa interferon therapy. Ribavirin monotherapy is not effective and must be used in combination with interferon.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9493035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peginterferon Alfa-2a:",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9493036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Ribavirin may enhance the adverse/toxic effect of Didanosine. Ribavirin may increase serum concentrations of the active metabolite(s) of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine: Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine. This only pertains to live, attenuated influenza virus vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Nucleoside): Ribavirin may enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Concomitant use of interferons with telbivudine may increase the risk for serious peripheral neuropathy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. Exceptions: Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9491716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during pregnancy is contraindicated. Abortifacient and teratogenic effects have been reported in women receiving interferons. Women of childbearing potential should not be treated unless two reliable forms of contraception are used. In addition, male patients and their female partners must also use two reliable forms of contraception. Pregnancy must be avoided during treatment and for 6 months following therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9491718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9493373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take ribavirin with food.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9493377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obtain pretreatment CBC, liver function tests, renal function, lipids, TSH, and electrolytes, then monitor routinely throughout therapy (at 2- and 4 weeks, more frequently if indicated); discontinue if neutrophils &lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, platelets &lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, or if hemoglobin &lt;8.5 g/dL (in cardiac patients, discontinue if hemoglobin &lt;12 g/dL after 4 weeks of dosage reduction). Pretreatment and monthly pregnancy test (up to 6 months following therapy discontinuation) for women of childbearing age. Baseline chest x-ray, ECG, weight; patients with pre-existing cardiac abnormalities should have an ECG before and during treatment; glucose (diabetic or symptomatic patients), I &amp; O; dental exams; neuropsychiatric monitoring; vision (pretreatment and periodic during therapy) and hearing evaluations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum HCV RNA levels (pretreatment, 4-, 12-, and 24 weeks after therapy initiation, 24 weeks after completion of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In addition, the following baseline values were used as entrance criteria in clinical trials:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Platelet count &ge;90 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L (as low as 75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L in patients with cirrhosis or transition to cirrhosis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serum creatinine &lt;1.5 times ULN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TSH and T",
"     <sub>",
"      4",
"     </sub>",
"     within normal limits or adequately controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;200 cells/microL or CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;100 cells/microL, but &lt;200 cells/microL and HIV-1 RNA &lt;5000 copies/mL in CHC-HIV coinfected patients",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9493364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canadian consensus guidelines (Sherman, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rapid virological response (RVR): HCV RNA negative (&lt;50 units/mL) after 4 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Early virological response (EVR):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Early virological clearance (EVC): HCV RNA negative (&lt;50 units/mL) after 12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Partial virological response (PVR): HCV RNA positive but &ge;2 log decrease in HCV RNA after 12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained virological response (SVR): Absence of HCV RNA in the serum 6 months following completion of full treatment course",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9493042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2a: Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9493365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg T, Von Wagner M, Nasser S, et al, &ldquo;Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(4):1086-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1272/abstract-text/16618403/pubmed\" id=\"16618403\" target=\"_blank\">",
"        16618403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1272/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management and Treatment of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1272/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(23):2444-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1272/abstract-text/17151366/pubmed\" id=\"17151366\" target=\"_blank\">",
"        17151366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearlman BL, Ehleben C, and Saifee S, &ldquo;Treatment Extension to 72 Weeks of Peginterferon and Ribavirin in Hepatitis C Genotype 1-Infected Slow Responders,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2007, 46(6):1688-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1272/abstract-text/18046717/pubmed\" id=\"18046717\" target=\"_blank\">",
"        18046717",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherman M, Shafran S, Burak K, et al, &ldquo;Management of Chronic Hepatitis C: Consensus Guidelines,&rdquo;",
"      <i>",
"       Can J Gastroenterology",
"      </i>",
"      , 2007, 21(Suppl C):25-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/15/1272/abstract-text/17568823/pubmed\" id=\"17568823\" target=\"_blank\">",
"        17568823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9525 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1272=[""].join("\n");
var outline_f1_15_1272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491710\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491713\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13503087\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9494669\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493369\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493370\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493368\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493424\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234134\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493374\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491715\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491866\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491719\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491720\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493035\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493036\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491716\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491718\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493373\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493377\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493364\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493042\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9493365\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9525\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9525|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/16/44294?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a and ribavirin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_15_1273="Etiology and pathogenesis of infantile spasms";
var content_f1_15_1273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and pathogenesis of infantile spasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/15/1273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1273/contributors\">",
"     Daniel G Glaze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/15/1273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1273/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/15/1273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/15/1273/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/15/1273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile spasms (IS) is an age-specific (most patients have onset between 3 and 8 months of age) epileptic disorder of infancy and early childhood. Children with IS typically exhibit the electroencephalographic pattern known as hypsarhythmia. The combination of IS with hypsarhythmia is referred to as West syndrome. IS has been used to refer to either a seizure type or an epilepsy syndrome. Patients with the syndrome of IS may have other seizure types; also, seizures similar to IS may occur in other epileptic syndromes.",
"   </p>",
"   <p>",
"    While relatively rare, IS is a significant disorder because of its strong association with developmental delay or regression (75 to 93 percent of affected children), high mortality rate, refractoriness to conventional antiepileptic drugs, and responsiveness to hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, etiology, pathogenesis, and pathology of IS are reviewed here. The clinical features and diagnosis, and management and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"     \"Clinical features and diagnosis of infantile spasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;IS is a rare disorder with an incidence of 1.6 to 4.5 per 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In a cross-sectional, population-based surveillance system that included 21 EEG laboratories in Atlanta, Georgia, the incidence was 2.9 per 10,000 live births among children born in 1975 to 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence among 10-year-old children was 2.0 per 10,000; the lower prevalence than incidence likely reflecting the substantial mortality of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. However, a history of IS was found in a substantial proportion, 12 percent, of children with profound mental retardation.",
"   </p>",
"   <p>",
"    Period changes in incidence rates of IS are stable over time in some reports but variable in others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/4,5,7,8\">",
"     4,5,7,8",
"    </a>",
"    ]. The differences are likely due in part to the relatively small numbers of patients. In a study of 57 patients from Finland during the period of 1960 to 1992, the incidence remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/8\">",
"     8",
"    </a>",
"    ]. In a report from Canada that included 75 patients recorded over a 20-year period, annual and five-year incidence rates varied [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/7\">",
"     7",
"    </a>",
"    ]. During two consecutive periods (1979 to 1992 and 1993 to 1998), the estimated average annual incidence decreased from 3.31 to 1.73 per 10,000 live births.",
"   </p>",
"   <p>",
"    Some studies have found that boys and girls appear to be affected equally [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/3,7\">",
"     3,7",
"    </a>",
"    ], while others suggest that boys are somewhat more likely to be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IS occurs in children of all ethnic groups. In the Atlanta, Georgia study mentioned above, IS occurred in similar proportions in Caucasian and African-American children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some patients with IS have an inherited disorder, such as tuberous sclerosis, most cases are sporadic. A family history of IS is positive in 1 to 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/9\">",
"     9",
"    </a>",
"    ]. A genetic susceptibility that is multifactorial appears to exist [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. However, environmental factors such as anoxia or birth trauma may be required to precipitate seizures.",
"   </p>",
"   <p>",
"    Recurrence rates with families without a defined genetic syndrome vary depending upon the features associated with IS. In one study of 77 families, the empiric recurrence risk of IS among siblings was estimated as 15 per 1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/10\">",
"     10",
"    </a>",
"    ]. In a report that excluded familial diseases, the recurrence risk for the idiopathic or cryptogenic group (IS with prior normal development and no known etiology) was &lt;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific genes that have recently been discovered to be associated with infantile spasms include those encoding the forkhead protein G1 (FOXG1) and the syntaxin-binding protein 1 (STXBP1) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/11,14-16\">",
"     11,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10898979\">",
"    <span class=\"h2\">",
"     X-linked infantile spasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare families demonstrate X-linked inheritance of IS.",
"   </p>",
"   <p>",
"    Mutations in the Aristaless-related homeobox (ARX) gene (which maps to Xp21.3-Xp22.1) are associated with a familial syndrome of IS, severe mental retardation, and subsequent epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Other affected members within the same family may have variant syndromes with some combination of mental retardation along with dystonia, myoclonic seizures, lissencephaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal genitalia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other loci have been identified. Two severely affected unrelated female patients with IS had balanced X:autosome translocations disrupting the gene encoding serine-threonine kinase 9 (STK9), also known as cyclin-dependent kinase-like 5 (CDKL5) (which maps to Xp22.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Mutations in this gene have been reported in individuals with severe neurodevelopmental disorders including a Rett syndrome-like phenotype and early-onset seizures including infantile spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate genetic testing is available for X-linked infantile spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/24\">",
"     24",
"    </a>",
"    ]. Further information is available at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     file://www.genetests.org",
"    </a>",
"    . Counselling for genetic testing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12549509\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of IS is evolving. Traditionally, IS is typically classified as symptomatic versus cryptogenic:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with symptomatic IS have an identified etiology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant developmental delay at the time of spasm onset.",
"     </li>",
"     <li>",
"      Patients with cryptogenic IS have no known etiology and normal development at the time of spasm onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ILAE Workshop on IS proposed the addition of an idiopathic group. This category includes patients with normal development at onset, normal examination and neuroimaging, and hypsarrhythmic EEG pattern without focal epileptiform abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of etiologic categories of IS varies among reports. This wide range results from use of different definitions, the early age at diagnosis when neurodevelopmental status may be difficult to assess, and the increased use of neuroimaging studies that reveal an underlying cause in most cases. In a report from the Canadian provinces of Nova Scotia and Prince Edward Island from 1978 to 1998, the proportion of etiologic categories was 68, 24, and 8 percent for symptomatic, cryptogenic, and idiopathic, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in a series of 140 affected patients whose evaluation included computed tomography (CT), magnetic resonance imaging (MRI),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positron emission tomography (PET), 96 percent of the cases were classified as symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/27\">",
"     27",
"    </a>",
"    ]. The medical evaluation of these patients was somewhat more extensive than is typical; it is unlikely that as high a proportion of patients evaluated in the community would be classified as symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptomatic infantile spasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic IS results from a known or suspected central nervous system (CNS) disorder. One or more etiologic factors can be identified in the majority (60 to 70 percent) of cases of IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/28\">",
"     28",
"    </a>",
"    ]. Follow-up evaluation with neuroimaging and PET may increase the proportion with a known cause to as high as 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The critical time of the insult typically occurs in the prenatal, perinatal, or early postnatal period. Prenatal factors account for the greatest proportion of cases of West syndrome, 43 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The most common prenatal abnormality is a malformation of the CNS. Others include chromosome and other genetic disorders, neurocutaneous disorders, inborn errors of metabolism, and intrauterine infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CNS malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical dysplasia is the most common disorder, estimated to account for 30 percent of prenatal causes of IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/28\">",
"     28",
"    </a>",
"    ]. Other CNS malformations that may result in IS include cerebral dysgenesis (eg, Aicardi syndrome), lissencephaly (eg, Miller-Dieker syndromes), holoprosencephaly, and hemimegalencephaly. Nearly all patients with Miller-Dieker syndrome and Aicardi syndrome have IS at some stage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miller-Dieker syndrome &mdash; Miller-Dieker syndrome is caused by a disturbance in neuroblastic migration during CNS development, resulting in lissencephaly. Other features include growth retardation, microcephaly, craniofacial abnormalities (bitemporal grooving, micrognathia, ear anomalies, anteverted nares), renal and cardiac defects, and neurologic abnormalities (eg, hypotonia, infantile spasms, and mental retardation) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/33-42\">",
"       33-42",
"      </a>",
"      ]. Most patients with this disorder have a deletion of the gene located at 17p13.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aicardi syndrome &mdash; Aicardi syndrome is an X-linked dominant disorder. Because the condition is lethal in affected males, females are affected exclusively. The syndrome is characterized by infantile spasms (usually the presenting sign), agenesis of the corpus callosum, a distinctive chorioretinopathy, vertebral anomalies, and severe mental retardation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/44-47\">",
"       44-47",
"      </a>",
"      ]. Patients typically develop partial seizures before the age of 3 months; asymmetric IS develop some weeks to months later. Electroencephalography also often shows asymmetric hypsarhythmia.",
"     </li>",
"     <li>",
"      Hemimegalencephaly &mdash; Hemimegalencephaly is characterized by enlargement of one cerebral hemisphere with thickened and abnormal cortical structure on the affected side [",
"      <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/48\">",
"       48",
"      </a>",
"      ]. As many as half of patients with hemimegalencephaly develop infantile spasms, often in addition to other seizure types.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tuberous sclerosis complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberous sclerosis complex (TSC) is the neurocutaneous disorder most frequently associated with IS and accounts for 10 to 30 percent of prenatal causes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/28\">",
"     28",
"    </a>",
"    ]. IS occurs in as many as 68 percent of patients with TSC, and 7 to 25 percent of patients with IS have TSC [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/49-54\">",
"     49-54",
"    </a>",
"    ]. The actual incidence of TSC in children with IS may be even higher because the clinical signs of TSC may not be apparent when spasms first present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In general, patients with TSC and IS have an unfavorable outcome characterized by intractable epilepsy and severe cognitive dysfunction. In one report, development was normal in only 16 percent of 24 children with TSC and IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/28\">",
"     28",
"    </a>",
"    ]. Another series of 50 children reported a somewhat better outcome with mental retardation developing in 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/55\">",
"     55",
"    </a>",
"    ]. Risk factors for mental retardation were prolonged duration of IS, prolonged time from treatment initiation until the cessation of IS, and poor control of subsequent seizures after IS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5015707\">",
"    <span class=\"h3\">",
"     Other neurocutaneous disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neurocutaneous syndromes associated with IS include nevus linearis sebaceous, incontinentia pigmenti, Ito syndrome, and neurofibromatosis type I (NF1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link\">",
"     \"The genodermatoses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with NF1 and IS generally have symmetric spasms, typical hypsarhythmia on EEG and no focal features. Compared with the combination of TSC and IS, outcome is better in patients with NF1 and IS, with resolution of IS with treatment in 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5015901\">",
"    <span class=\"h3\">",
"     Chromosome abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosome abnormalities accounted for 15 percent of prenatal etiologies of West syndrome in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/31\">",
"     31",
"    </a>",
"    ]. Down syndrome (trisomy 21) was the most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IS is a common seizure type in patients with Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In one series of 350 children with Down syndrome, 28 (8 percent) had seizures; 13 had IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/58\">",
"     58",
"    </a>",
"    ]. In general, neurodevelopmental outcome in these patients is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This may be modifiable with early recognition and treatment; in one retrospective study of IS in children with Down syndrome, longer lead-times to treatment of IS were associated with lower developmental quotient and higher scores of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link&amp;anchor=H30#H30\">",
"     \"Management and prognosis of infantile spasms\", section on 'Prognosis'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Other chromosome abnormalities linked to IS include 18q duplication, 7q duplication, as well as a deletion of the MAGI2 gene on chromosome 7q11.23-q21.11, and partial 2p trisomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Inborn errors of metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inborn errors of metabolism may be associated with IS.",
"   </p>",
"   <p>",
"    In countries where phenylketonuria (PKU) is not detected by newborn metabolic screening, IS is a common manifestation of this disorder. In a report from Beijing, China, West syndrome occurred in 62 of 503 patients with PKU (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/62\">",
"     62",
"    </a>",
"    ]. In this series, the diagnosis of PKU was made in patients 4 months to 7 years of age, with the onset of IS occurring prior to diagnosis in most cases. Dietary intervention reduced the frequency of spasms and improved cognitive outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"     \"Overview of phenylketonuria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IS has been associated with more than 25 other metabolic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/64\">",
"     64",
"    </a>",
"    ]. These include dihydropteridine reductase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/65\">",
"     65",
"    </a>",
"    ], Menkes disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], pyruvate dehydrogenase complex deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/68\">",
"     68",
"    </a>",
"    ], cytochrome c oxidase deficiency (Leigh syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/69\">",
"     69",
"    </a>",
"    ], histidinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/70\">",
"     70",
"    </a>",
"    ], pyridoxine deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/63\">",
"     63",
"    </a>",
"    ], and urea cycle disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Congenital infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;IS can occur in infants with congenital infections affecting the CNS. These include toxoplasmosis, syphilis, and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/8,72,73\">",
"     8,72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H650131395#H650131395\">",
"     \"Overview of TORCH infections\", section on 'Clinical features of TORCH infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Perinatal causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;IS may be associated with perinatal insults, including hypoxic ischemic encephalopathy and neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/8,74\">",
"     8,74",
"    </a>",
"    ]. In one series of 32 patients with IS and a history of perinatal insults, 15 had porencephalic lesions, 12 (all premature) had periventricular leukomalacia, and 5 had diffuse bilateral cerebral atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/75\">",
"     75",
"    </a>",
"    ]. In one study of 17 term and near-term infants with hypoxic ischemic encephalopathy, 5 developed West syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/76\">",
"     76",
"    </a>",
"    ]. Prolonged EEG depression over 21 days of age was an important predictor of West syndrome in this small series. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"     \"Periventricular leukomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between IS and preterm birth is uncertain. Among children with IS, the rate of low birth weight is approximately three to four times that of the general population, although the rate of prematurity is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/8,72\">",
"     8,72",
"    </a>",
"    ]. This may be because IS is more likely to occur in infants who are small for gestational age than in preterm infants of appropriate weight [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/77\">",
"     77",
"    </a>",
"    ]. However, the apparent increase in IS attributed to perinatal causes may result from the improved survival of very-low-birth-weight infants, including those with periventricular leukomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Postnatal insults",
"    </span>",
"    &nbsp;&mdash;&nbsp;IS has been attributed to postnatal insults in 15 percent to 67 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/8,32,72,74\">",
"     8,32,72,74",
"    </a>",
"    ]. These include traumatic injury, near drowning, tumors, and CNS infections, including bacterial meningitis and viral encephalitis. In one literature review, these events typically occurred within the first year of life, but were reported as late as 31 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/74\">",
"     74",
"    </a>",
"    ]. The latency between the insult and the onset of IS ranged from 1.5 to 11 months (mean 5.1 months).",
"   </p>",
"   <p>",
"    However, in rare cases, IS occurs after a later event, as illustrated by case reports of two children with previously normal development who developed IS at 20 and 34 months of age after near drowning at 16 and 31 months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No data support a causal relationship between IS and immunizations for pertussis or other childhood diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cryptogenic (probably symptomatic) infantile spasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologic categorization of IS is evolving. A 2001 proposal suggested the term &ldquo;probably symptomatic&rdquo; in preference to cryptogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/26\">",
"     26",
"    </a>",
"    ]. This refers to patients with IS who are presumed to have a symptomatic cause, but this has not been identified. Traditionally, criteria for cryptogenic IS are [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      normal development before onset of symmetric spasms",
"     </li>",
"     <li>",
"      no other kind of seizure",
"     </li>",
"     <li>",
"      normal examination",
"     </li>",
"     <li>",
"      normal CT and MRI",
"     </li>",
"     <li>",
"      recurrence of hypsarrhythmia between consecutive spasms of a cluster",
"     </li>",
"     <li>",
"      lack of any focal interictal or ictal EEG abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proportion of affected infants with cryptogenic IS ranges from 4 to 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/6,28,82\">",
"     6,28,82",
"    </a>",
"    ]. This wide range results from the use of different definitions, the early age at diagnosis when neurodevelopmental status may be difficult to assess, and the increased use of neuroimaging studies that may reveal an underlying cause. Although IS may appear to be cryptogenic at the initial presentation, neuroimaging can identify an etiology in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of infantile spasms\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This subset of IS appears to have a better prognosis than patients with symptomatic IS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link&amp;anchor=H30#H30\">",
"     \"Management and prognosis of infantile spasms\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261004954\">",
"    <span class=\"h2\">",
"     Idiopathic infantile spasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ILAE Workshop on IS proposed the addition of an idiopathic group. This category includes patients with normal development at onset, normal examination and neuroimaging, and hypsarrhythmic EEG pattern without focal epileptiform abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. These syndromes are typically presumed to have a genetic basis. Studies that have classified IS into symptomatic versus cryptogenic included this patient group in the latter category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of IS is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. The development of animal models will likely contribute to our understanding of mechanisms underlying IS [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IS, an age-specific disorder, is thought to result from a nonspecific insult at a critical point in the ontogenetic development of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/84\">",
"     84",
"    </a>",
"    ]. The age at onset of spasms appears to correlate with the location of focal cerebral lesions and follows the normal sequence of brain maturation. This correlation was illustrated by a series of 93 patients who had lesions confined to one of three regions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/85\">",
"     85",
"    </a>",
"    ]. The mean age of onset of IS was 3.4, 6.3, and 9.8 months for occipital, centro-temporo-parietal, or frontal lesions, respectively, which follows the pattern of functional brain development.",
"   </p>",
"   <p>",
"    The responsiveness of IS to treatment with corticotropin (ACTH) suggests a possible role for abnormalities in the hypothalamic-pituitary-adrenal axis in the pathogenesis of IS (perhaps a brain insult activating a neuroendocrine stress response), but this has not been specifically elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Disturbed immune activation has also been hypothesized to play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also uncertain whether the epileptic spasms are generated primarily in the cerebral hemispheres or the brainstem. A cortical origin is supported by neuropathologic changes in the cerebral hemispheres in autopsy studies and surgical specimens, as well as abnormalities seen on neuroimaging studies and EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/90-100\">",
"     90-100",
"    </a>",
"    ]. Resolution of IS following cortical surgical resection also supports this origin. However, other findings suggest that IS may originate in the brainstem or in other subcortical structures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/9\">",
"     9",
"    </a>",
"    ]. These findings include some autopsy studies, the prominent sleep disturbance in IS, as well as observed patterns of neurotransmitter abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/15/1273/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12549614\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infantile spasms (IS) is an age-specific epileptic disorder of infancy and early childhood. Distinctive clinical features include onset between 3 and 8 months of age in most patients, a high association with developmental retardation, a high mortality rate, refractoriness to conventional antiepileptic drugs, and unique responsiveness to hormonal therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"       \"Clinical features and diagnosis of infantile spasms\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=see_link\">",
"       \"Management and prognosis of infantile spasms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IS is a rare disorder with an incidence of 1.6 to 4.5 per 10,000 live births. IS occurs in children of all ethnic groups. There is no clear predilection for either gender. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While most cases of IS are sporadic, IS may be a manifestation of certain inherited disorders including tuberous sclerosis and other neurocutaneous syndromes. Nonetheless, a genetic susceptibility is believed to play a role in the pathogenesis of the disorder. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IS is typically classified as symptomatic (patients have an identified etiology) versus cryptogenic (patients have no known etiology and normal development at the time of spasm onset). The classification scheme is evolving and some investigators include an idiopathic group. (See",
"      <a class=\"local\" href=\"#H12549509\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most cases (with best estimates between 60 to 70 percent) are symptomatic.",
"     </li>",
"     <li>",
"      Prenatal factors (eg, brain malformations, chromosome and other genetic disorders, neurocutaneous disorders) account for the greatest proportion of symptomatic cases. Perinatal and postnatal insults are causative in others.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of IS is unknown and is likely to be multifactorial. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/1\">",
"      Van der Berg BJ, Yerushalmy J. Studies on convulsive disorders in young children. I. Incidence of febrile and nonfebrile convulsions by age and other factors. Pediatr Res 1969; 3:298.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson, K. Discussion: The Epidemiology of Epilepsy: A Workshop 1972.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/3\">",
"      Trevathan E, Murphy CC, Yeargin-Allsopp M. The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia 1999; 40:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/4\">",
"      Sidenvall R, Eeg-Olofsson O. Epidemiology of infantile spasms in Sweden. Epilepsia 1995; 36:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/5\">",
"      L&uacute;thv&iacute;gsson P, Olafsson E, Sigurthard&oacute;ttir S, Hauser WA. Epidemiologic features of infantile spasms in Iceland. Epilepsia 1994; 35:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/6\">",
"      Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/7\">",
"      Brna PM, Gordon KE, Dooley JM, Wood EP. The epidemiology of infantile spasms. Can J Neurol Sci 2001; 28:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/8\">",
"      Riikonen R. Epidemiological data of West syndrome in Finland. Brain Dev 2001; 23:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/9\">",
"      Hrachovy RA, Frost JD Jr. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome). J Clin Neurophysiol 2003; 20:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/10\">",
"      Fleiszar KA, Daniel WL, Imrey PB. Genetic study of infantile spasm with hypsarrhythmia. Epilepsia 1977; 18:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/11\">",
"      Otsuka M, Oguni H, Liang JS, et al. STXBP1 mutations cause not only Ohtahara syndrome but also West syndrome--result of Japanese cohort study. Epilepsia 2010; 51:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/12\">",
"      Paciorkowski AR, Thio LL, Dobyns WB. Genetic and biologic classification of infantile spasms. Pediatr Neurol 2011; 45:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/13\">",
"      Dulac O, Feingold J, Plouin P, et al. Genetic predisposition to West syndrome. Epilepsia 1993; 34:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/14\">",
"      Striano P, Paravidino R, Sicca F, et al. West syndrome associated with 14q12 duplications harboring FOXG1. Neurology 2011; 76:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/15\">",
"      Tohyama J, Yamamoto T, Hosoki K, et al. West syndrome associated with mosaic duplication of FOXG1 in a patient with maternal uniparental disomy of chromosome 14. Am J Med Genet A 2011; 155A:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/16\">",
"      Mignot C, Moutard ML, Trouillard O, et al. STXBP1-related encephalopathy presenting as infantile spasms and generalized tremor in three patients. Epilepsia 2011; 52:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/17\">",
"      Bienvenu T, Poirier K, Friocourt G, et al. ARX, a novel Prd-class-homeobox gene highly expressed in the telencephalon, is mutated in X-linked mental retardation. Hum Mol Genet 2002; 11:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/18\">",
"      Str&oslash;mme P, Mangelsdorf ME, Shaw MA, et al. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet 2002; 30:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/19\">",
"      Bruyere H, Lewis S, Wood S, et al. Confirmation of linkage in X-linked infantile spasms (West syndrome) and refinement of the disease locus to Xp21.3-Xp22.1. Clin Genet 1999; 55:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/20\">",
"      Partington MW, Turner G, Boyle J, G&eacute;cz J. Three new families with X-linked mental retardation caused by the 428-451dup(24bp) mutation in ARX. Clin Genet 2004; 66:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/21\">",
"      Kato M, Das S, Petras K, et al. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat 2004; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/22\">",
"      Kalscheuer VM, Tao J, Donnelly A, et al. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet 2003; 72:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/23\">",
"      Sprovieri T, Conforti FL, Fiumara A, et al. A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype. Am J Med Genet A 2009; 149A:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/24\">",
"      Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies--report of the ILAE Genetics Commission. Epilepsia 2010; 51:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/25\">",
"      Commission on Classification and Terminology of the International League Against Epilepsy: Workshop on infantile spasms. Epilepsia 1992; 33:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/26\">",
"      Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004; 45:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/27\">",
"      Chugani HT, Conti JR. Etiologic classification of infantile spasms in 140 cases: role of positron emission tomography. J Child Neurol 1996; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/28\">",
"      Watanabe K. West syndrome: etiological and prognostic aspects. Brain Dev 1998; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/29\">",
"      van Bogaert P, Chiron C, Adamsbaum C, et al. Value of magnetic resonance imaging in West syndrome of unknown etiology. Epilepsia 1993; 34:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/30\">",
"      Aydinli N, Calikan M, Ozmen M, Tongu&ccedil; E. Neuroradiologic aspects of West syndrome. Pediatr Neurol 1998; 19:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/31\">",
"      Ohtahara S, Ohtsuka Y, Yamatogi Y, et al. Prenatal etiologies of West syndrome. Epilepsia 1993; 34:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/32\">",
"      Osborne JP, Lux AL, Edwards SW, et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia 2010; 51:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/33\">",
"      MILLER JQ. LISSENCEPHALY IN 2 SIBLINGS. Neurology 1963; 13:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/34\">",
"      Dieker, H, Edwards, RH, ZuRhein, G, et al. The lissencephaly syndrome. Birth Defects: Original Article Series 1969; 5:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/35\">",
"      Jones KL, Gilbert EF, Kaveggia EG, Opitz JM. The MIller-Dieker syndrome. Pediatrics 1980; 66:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/36\">",
"      Van Allen M, Clarren SK. A spectrum of gyral anomalies in Miller-Dieker (lissencephaly) syndrome. J Pediatr 1983; 102:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/37\">",
"      Dobyns WB, Stratton RF, Parke JT, et al. Miller-Dieker syndrome: lissencephaly and monosomy 17p. J Pediatr 1983; 102:552.",
"     </a>",
"    </li>",
"    <li>",
"     Warkany, J, Lemire, RJ, Cohen, MM. Lissencephaly: agyria and pachygyria, Year Book Medical Publishers, Chicago 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/39\">",
"      Harper JR. Infantile spasms associated with cerebral agyria. Dev Med Child Neurol 1967; 9:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/40\">",
"      Jellinger K, Rett A. Agyria-pachygyria (lissencephaly syndrome). Neuropadiatrie 1976; 7:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/41\">",
"      Garcia CA, Dunn D, Trevor R. The lissencephaly (agyria) syndrome in siblings. Computerized tomographic and neuropathologic findings. Arch Neurol 1978; 35:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/42\">",
"      Ohno K, Enomoto T, Imamoto J, et al. Lissencephaly (agyria) on computed tomography. J Comput Assist Tomogr 1979; 3:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/43\">",
"      Singh R, Gardner RJ, Crossland KM, et al. Chromosomal abnormalities and epilepsy: a review for clinicians and gene hunters. Epilepsia 2002; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/44\">",
"      Aicardi J, Chevrie JJ, Rousselie F. [Spasma-in-flexion syndrome, callosal agenesis, chorioretinal abnormalities]. Arch Fr Pediatr 1969; 26:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/45\">",
"      Dennis J, Bower BD. The Aicardi syndrome. Dev Med Child Neurol 1972; 14:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/46\">",
"      Bertoni JM, von Loh S, Allen RJ. The Aicardi syndrome: report of 4 cases and review of the literature. Ann Neurol 1979; 5:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/47\">",
"      Willis J, Rosman NP. The Aicardi syndrome versus congenital infection: diagnostic considerations. J Pediatr 1980; 96:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/48\">",
"      Guerrini R, Sicca F, Parmeggiani L. Epilepsy and malformations of the cerebral cortex. Epileptic Disord 2003; 5 Suppl 2:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/49\">",
"      Rizzuto N, Ferrari G. Familial infantile myoclonic epilepsy in a family suffering from tuberous sclerosis. Epilepsia 1968; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/50\">",
"      Roth JC, Epstein CJ. Infantile spasms and hypopigmented macules. Early manifestations of tuberous sclerosis. Arch Neurol 1971; 25:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/51\">",
"      Nevin NC, Pearce WG. Diagnostic and genetical aspects of tuberous sclerosis. J Med Genet 1968; 5:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/52\">",
"      DELLAROVERE M, HOARE RD, PAMPIGLIONE G. TUBEROSE SCLEROSIS IN CHILDREN: AN EEG STUDY. Dev Med Child Neurol 1964; 6:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/53\">",
"      Fois A, Pindinelli CA, Berardi R. Early signs of tuberous sclerosis in infancy and childhood. Helv Paediatr Acta 1973; 28:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/54\">",
"      Curatolo P, Seri S, Verdecchia M, Bombardieri R. Infantile spasms in tuberous sclerosis complex. Brain Dev 2001; 23:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/55\">",
"      Goh S, Kwiatkowski DJ, Dorer DJ, Thiele EA. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 2005; 65:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/56\">",
"      Motte J, Billard C, Fejerman N, et al. Neurofibromatosis type one and West syndrome: a relatively benign association. Epilepsia 1993; 34:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/57\">",
"      Escofet C, P&oacute;o P, Valbuena O, et al. [Infantile spasms in children with Down's syndrome]. Rev Neurol 1995; 23:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/58\">",
"      Goldberg-Stern H, Strawsburg RH, Patterson B, et al. Seizure frequency and characteristics in children with Down syndrome. Brain Dev 2001; 23:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/59\">",
"      Silva ML, Cieuta C, Guerrini R, et al. Early clinical and EEG features of infantile spasms in Down syndrome. Epilepsia 1996; 37:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/60\">",
"      Eisermann MM, DeLaRaill&egrave;re A, Dellatolas G, et al. Infantile spasms in Down syndrome--effects of delayed anticonvulsive treatment. Epilepsy Res 2003; 55:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/61\">",
"      Marshall CR, Young EJ, Pani AM, et al. Infantile spasms is associated with deletion of the MAGI2 gene on chromosome 7q11.23-q21.11. Am J Hum Genet 2008; 83:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/62\">",
"      Zhongshu Z, Weiming Y, Yukio F, et al. Clinical analysis of West syndrome associated with phenylketonuria. Brain Dev 2001; 23:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/63\">",
"      LOW NL, BOSMA JF, ARMSTRONG MD, MADSEN JA. Infantile spasms with mental retardation. I. Clinical observations and dietary experiments. Pediatrics 1958; 22:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/64\">",
"      Gkampeta A, Pavlou E. Infantile spasms (West syndrome) in children with inborn errors of metabolism: a review of the literature. J Child Neurol 2012; 27:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/65\">",
"      Mikaeloff Y, Plouin P, Dhondt JL, et al. Clinical and EEG video-polygraphic features of epileptic spasms in a child with dihydropteridine reductase deficiency. Efficiency of hydrocortisone. Epileptic Disord 2000; 2:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/66\">",
"      Sfaello I, Castelnau P, Blanc N, et al. Infantile spasms and Menkes disease. Epileptic Disord 2000; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/67\">",
"      Bahi-Buisson N, Kaminska A, Nabbout R, et al. Epilepsy in Menkes disease: analysis of clinical stages. Epilepsia 2006; 47:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/68\">",
"      Naito E, Ito M, Yokota I, et al. Gender-specific occurrence of West syndrome in patients with pyruvate dehydrogenase complex deficiency. Neuropediatrics 2001; 32:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/69\">",
"      Tsao CY, Luquette M, Rusin JA, et al. Leigh syndrome, cytochrome C oxidase deficiency and hypsarrhythmia with infantile spasms. Clin Electroencephalogr 1997; 28:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/70\">",
"      Duffner PK, Cohen ME. Infantile spasms associated with histidinemia. Neurology 1975; 25:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/71\">",
"      Shih VE, Efron ML, Moser HW. Hyperornithinemia, hyperammonemia, and homocitrullinuria. A new disorder of amino acid metabolism associated with myoclonic seizures and mental retardation. Am J Dis Child 1969; 117:83.",
"     </a>",
"    </li>",
"    <li>",
"     Lacy JR, Penry JK. Infantile spasms, Raven Press, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/73\">",
"      Feldman, RA, Schwartz, JF. Possible association between cytomegalovirus infection and infantile spasms. Lancet 1968; 1:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/74\">",
"      Guggenheim MA, Frost JD Jr, Hrachovy RA. Time interval from a brain insult to the onset of infantile spasms. Pediatr Neurol 2008; 38:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/75\">",
"      Cusmai R, Ricci S, Pinard JM, et al. West syndrome due to perinatal insults. Epilepsia 1993; 34:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/76\">",
"      Kato T, Okumura A, Hayakawa F, et al. Prolonged EEG depression in term and near-term infants with hypoxic ischemic encephalopathy and later development of West syndrome. Epilepsia 2010; 51:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/77\">",
"      Riikonen R. Decreasing perinatal mortality: unchanged infantile spasm morbidity. Dev Med Child Neurol 1995; 37:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/78\">",
"      Hrachovy RA, Frost JD Jr, Gospe SM Jr, Glaze DG. Infantile spasms following near-drowning: a report of two cases. Epilepsia 1987; 28:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/79\">",
"      Howson CP, Fineberg HV. Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. JAMA 1992; 267:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/80\">",
"      Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994; 271:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/81\">",
"      Commission on classification and terminology of the International League Against Epilepsy. Workshop on infantile spasms. Epilepsia 1992; 33:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/82\">",
"      Glaze DG, Hrachovy RA, Frost JD Jr, et al. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988; 112:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/83\">",
"      Stafstrom CE, Holmes GL. Infantile spasms: criteria for an animal model. Int Rev Neurobiol 2002; 49:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/84\">",
"      Frost JD Jr, Hrachovy RA. Pathogenesis of infantile spasms: a model based on developmental desynchronization. J Clin Neurophysiol 2005; 22:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/85\">",
"      Koo B, Hwang P. Localization of focal cortical lesions influences age of onset of infantile spasms. Epilepsia 1996; 37:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/86\">",
"      Baram TZ, Mitchell WG, Brunson K, Haden E. Infantile spasms: hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists. Dev Neurosci 1999; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/87\">",
"      Vel&iacute;sek L, Jehle K, Asche S, Vel&iacute;skov&aacute; J. Model of infantile spasms induced by N-methyl-D-aspartic acid in prenatally impaired brain. Ann Neurol 2007; 61:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/88\">",
"      Haginoya K, Noguchi R, Zhao Y, et al. Reduced levels of interleukin-1 receptor antagonist in the cerebrospinal fluid in patients with West syndrome. Epilepsy Res 2009; 85:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/89\">",
"      Yamanaka G, Kawashima H, Oana S, et al. Increased level of serum interleukin-1 receptor antagonist subsequent to resolution of clinical symptoms in patients with West syndrome. J Neurol Sci 2010; 298:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/90\">",
"      Jellinger K. Neuropathological aspects of infantile spasms. Brain Dev 1987; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/91\">",
"      Vinters HV, De Rosa MJ, Farrell MA. Neuropathologic study of resected cerebral tissue from patients with infantile spasms. Epilepsia 1993; 34:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/92\">",
"      Juh&aacute;sz C, Chugani HT, Muzik O, Chugani DC. Neuroradiological assessment of brain structure and function and its implication in the pathogenesis of West syndrome. Brain Dev 2001; 23:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/93\">",
"      Watanabe K, Negoro T, Okumura A. Symptomatology of infantile spasms. Brain Dev 2001; 23:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/94\">",
"      Hwang PA, Otsubo H, Koo BK, et al. Infantile spasms: cerebral blood flow abnormalities correlate with EEG, neuroimaging, and pathologic findings. Pediatr Neurol 1996; 14:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/95\">",
"      Chiron C, Dulac O, Bulteau C, et al. Study of regional cerebral blood flow in West syndrome. Epilepsia 1993; 34:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/96\">",
"      Chugani HT, Shields WD, Shewmon DA, et al. Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Ann Neurol 1990; 27:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/97\">",
"      Jambaqu&eacute; I, Chiron C, Dulac O, et al. Visual inattention in West syndrome: a neuropsychological and neurofunctional imaging study. Epilepsia 1993; 34:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/98\">",
"      Munakata M, Haginoya K, Ishitobi M, et al. Dynamic cortical activity during spasms in three patients with West syndrome: a multichannel near-infrared spectroscopic topography study. Epilepsia 2004; 45:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/99\">",
"      Asano E, Juh&aacute;sz C, Shah A, et al. Origin and propagation of epileptic spasms delineated on electrocorticography. Epilepsia 2005; 46:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/100\">",
"      Dulac O, Chiron C, Robain O, et al. Infantile spasms: a pathophysiological hypothesis. Semin Pediatr Neurol 1994; 1:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/101\">",
"      Satoh J, Mizutani T, Morimatsu Y. Neuropathology of the brainstem in age-dependent epileptic encephalopathy--especially of cases with infantile spasms. Brain Dev 1986; 8:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/102\">",
"      Hrachovy RA, Frost JD Jr, Kellaway P. Sleep characteristics in infantile spasms. Neurology 1981; 31:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/15/1273/abstract/103\">",
"      Hayashi M, Itoh M, Araki S, et al. Immunohistochemical analysis of brainstem lesions in infantile spasms. Neuropathology 2000; 20:297.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6163 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1273=[""].join("\n");
var outline_f1_15_1273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12549614\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10898979\">",
"      X-linked infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12549509\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptomatic infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CNS malformations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tuberous sclerosis complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5015707\">",
"      - Other neurocutaneous disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5015901\">",
"      - Chromosome abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Congenital infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Perinatal causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Postnatal insults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cryptogenic (probably symptomatic) infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261004954\">",
"      Idiopathic infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12549614\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_15_1274="Donut mastopexy";
var content_f1_15_1274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Donut mastopexy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 728px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Donut mastopexy lumpectomy, medial breast lesion.",
"    <br>",
"     (A) Preoperative marking including marking of region to be removed based on preoperative bracketing wires and concentric circles for skin donut excision.",
"     <br>",
"      (B) Initial skin incision.",
"      <br>",
"       (C) Elevation of skin envelope dissecting in mastectomy plane.",
"       <br>",
"        (D) Mobilization of full-thickness wedge of disease-bearing broglandular tissue.",
"        <br>",
"         (E) Excised specimen and resulting broglandular defect.",
"         <br>",
"          (F) Mastopexy closure.",
"          <br>",
"           (G) Skin closure.",
"           <br>",
"            (H) Postoperative result.",
"            <div class=\"footnotes\">",
"            </div>",
"            <div class=\"reference\">",
"             Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"            </div>",
"            <div class=\"contractual\">",
"             <br/>",
"             <a href=\"file://www.lww.com\">",
"              file://www.lww.com",
"             </a>",
"            </div>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1274=[""].join("\n");
var outline_f1_15_1274=null;
var title_f1_15_1275="Composition hypoosmolar ORS";
var content_f1_15_1275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of hypo-osmolar oral rehydration solution (per one liter of clean water)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sodium chloride (NaCl)",
"       </td>",
"       <td>",
"        2.6 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium citrate",
"       </td>",
"       <td>",
"        2.9 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium chloride (KCl)",
"       </td>",
"       <td>",
"        1.5 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        13.5 g",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1275=[""].join("\n");
var outline_f1_15_1275=null;
var title_f1_15_1276="Funct level scale for Meniere disease";
var content_f1_15_1276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Functional level scale for Meniere disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Regarding my current state of overall function, not just during attacks (check the ONE that best applies):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. My dizziness has no effect on my activities at all.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. When I am dizzy I have to stop what I am doing for a while, but it soon passes and I can resume activities. I continue to work, drive, and engage in any activity I choose without restriction. I have not changed any plans or activities to accommodate my dizziness.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. When I am dizzy I have to stop what I am doing for a while, but it does pass and I can resume activities. I continue to work, drive, and engage in most activities I choose, but I have had to change some plans and make some allowance for my dizziness.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. I am able to work, drive, travel, take care of a family, or engage in most essential activities, but I must exert a great deal of effort to do so. I must constantly make adjustments in my activities and budget my energies. I am barely making it.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. I am unable to work, drive, or take care of a family. I am unable to do most of the active things that I used to. Even essential activities must be limited. I am disabled.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. I have been disabled for 1 year or longer and/or I receive compensation (money) because of my dizziness or balance problem.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113:181. Copyright &copy;1995 American Academy of Otolaryngology-Head and Neck Surgery.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1276=[""].join("\n");
var outline_f1_15_1276=null;
var title_f1_15_1277="Modern ALL protocols";
var content_f1_15_1277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methotrexate dose, duration of infusion, and leucovorin rescue for several modern ALL protocols",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose of methotrexate (MTX)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of methotrexate (MTX) infusion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Leucovorin rescue dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Start of leucovorin*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         DCLSG ALL VI",
"        </p>",
"        <p>",
"         Veerman, A; 1996",
"        </p>",
"       </td>",
"       <td>",
"        2g/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"       <td>",
"        25-75 mg q 6 hours",
"       </td>",
"       <td>",
"        36 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         BFM/DCLSG/ALL 8",
"        </p>",
"        <p>",
"         Kamps, W; 2002",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         2 gm/m",
"         <sup>",
"          2",
"         </sup>",
"         for SRG&bull;",
"        </p>",
"        <p>",
"         5 gm/m",
"         <sup>",
"          2",
"         </sup>",
"         for MRG&bull;",
"        </p>",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"       <td>",
"        15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        q 6 hours",
"       </td>",
"       <td>",
"        36-48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         JALSG-ALL 93",
"        </p>",
"        <p>",
"         Takeuchi, J; 2002",
"        </p>",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus then 500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        15 mg q 6 hours x 8 doses",
"       </td>",
"       <td>",
"        28 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         UCSF 8707",
"        </p>",
"        <p>",
"         Linker, C; 2002",
"        </p>",
"       </td>",
"       <td>",
"        220 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        bolus then 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per hour x 36 hours",
"       </td>",
"       <td>",
"        36 hours",
"       </td>",
"       <td>",
"        50 mg q 6 hours",
"       </td>",
"       <td>",
"        36 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         MRC UKALL XI",
"        </p>",
"        <p>",
"         Hill, F; 2004",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         6 gm/m",
"         <sup>",
"          2",
"         </sup>",
"         (age &lt;4)",
"        </p>",
"        <p>",
"         8 gm/m",
"         <sup>",
"          2",
"         </sup>",
"         (age &gt;4)",
"        </p>",
"       </td>",
"       <td>",
"        10 percent bolus, rest over 23 hours",
"       </td>",
"       <td>",
"        15 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        q 3 hours, then every 6 hours when serum MTX &lt;2 x 10",
"        <sup>",
"         6",
"        </sup>",
"        microM",
"       </td>",
"       <td>",
"        36 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         MDACC",
"        </p>",
"        <p>",
"         Kantarjian, H; 2004",
"        </p>",
"       </td>",
"       <td>",
"        1 gm/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"       <td>",
"        15 mg q 6 hours",
"       </td>",
"       <td>",
"        36 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         St Jude XIIIB",
"        </p>",
"        <p>",
"         Pui, C; 2004",
"        </p>",
"       </td>",
"       <td>",
"        2 gm/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        2 hours",
"       </td>",
"       <td>",
"        10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        q 6 hours",
"       </td>",
"       <td>",
"        44 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ALL: Acute lymphoblastic leukemia",
"    <div class=\"footnotes\">",
"     * After start of methotrexate (MTX).",
"     <br>",
"      &bull; SRG: standard risk group; MRG: medium risk group.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1277=[""].join("\n");
var outline_f1_15_1277=null;
var title_f1_15_1278="21 hydroxylase deficiency";
var content_f1_15_1278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 585px\">",
"   <div class=\"ttl\">",
"    Synthetic defect in CYP21A2 (21-hydroxylase) deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 565px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathways of adrenal steroid synthesis. A synthetic defect in 21-hydroxylase leads to diminished cortisol synthesis, increased release of ACTH, accumulation of 17-hydroxyprogesterone (particularly after the administration of ACTH), possible virilization due to increased androgen production, and possible salt-wasting due to diminished production of aldosterone and deoxycorticosterone.",
"    <div class=\"footnotes\">",
"     The numbers at the arrows refer to specific enzymes: 17&alpha;: 17&alpha;-hydroxylase (P450c17); 17,20: 17,20 lyase which is part of the P450c17 enzyme; 3&beta;: 3&beta;-hydroxysteroid dehydrogenase; 21: 21-hydroxylase (P450c21); 11&beta;: 11&beta;-hydroxylase; (P450c11); 18 refers to the two-step process of aldosterone synthase (P450c11as), resulting in the addition of an hydroxyl group that is then oxidized to an aldehyde group at the 18-carbon position; ?: unclear if pathway functions in vivo; DHEA: dehydroepiandrostenedione; 17KSR: 17-ketosteroid reductase; and A: aromatase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1278=[""].join("\n");
var outline_f1_15_1278=null;
var title_f1_15_1279="Cough method";
var content_f1_15_1279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Techniques for transbronchial penetration: cough method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram shows the cough method used for tracheobronchial wall penetration in transbronchoscopic needle aspiration. The fiberoptic bronchoscope and needle assembly are held stationary and the patient is asked to cough, which forces the tracheobronchial wall over the needle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research - Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_15_1279=[""].join("\n");
var outline_f1_15_1279=null;
